Ensuring Safe, Effective and Necessary Vaccines for Children by Horwin, Michael E.
California Western Law Review 
Volume 37 Number 2 Article 4 
2001 
Ensuring Safe, Effective and Necessary Vaccines for Children 
Michael E. Horwin 
Follow this and additional works at: https://scholarlycommons.law.cwsl.edu/cwlr 
Recommended Citation 
Horwin, Michael E. (2001) "Ensuring Safe, Effective and Necessary Vaccines for Children," California 
Western Law Review: Vol. 37 : No. 2 , Article 4. 
Available at: https://scholarlycommons.law.cwsl.edu/cwlr/vol37/iss2/4 
This Comment is brought to you for free and open access by CWSL Scholarly Commons. It has been accepted for 
inclusion in California Western Law Review by an authorized editor of CWSL Scholarly Commons. For more 
information, please contact alm@cwsl.edu. 
COMMENTS
ENSURING SAFE, EFFECTIVE AND NECESSARY
VACCINES FOR CHILDREN
On August 22, 1984 Sean Leary, a healthy nine-month old baby, was
administered his third DTP vaccine.' Later that afternoon, Sean began to
vomit.2 The next day, he stopped eating? He stayed alert but was no longer
active.' That night he cried out every fifteen to thirty minutes.' The following
day his mother took him to the pediatrician's office as soon as it opened."
The doctor immediately noted the "obvious circulation collapse."7 There at
the pediatrician's office, "Sean's eyes rolled back in his head and he stopped
breathing."8 He was rushed to an emergency room.9 Resuscitative efforts
failed and Sean was pronounced dead at 1:44 p.m.0 Sean's parents filed a
claim under the National Vaccine Injury Compensation Program and the de-
fendant hired an expert witness named Dr. Jerome Klein.1 Dr. Klein testified
that the relationship between the vaccination on August 22, and Sean's death
on August 24, was "merely coincidental."'2
In addition to testifying on behalf of vaccine manufacturers, Dr. Klein is
also the chief editor of "pneumo.com" a vaccine website paid for by Wyeth-
Lederle. 3 Wyeth-Lederle is the largest supplier of DTP in the country and
1. Leary v. Secretary of the Department of Health and Human Services, 1994 WL 43395,
at *1 (Fed. Cl. 1994).
2. Id.








11. A claim was filed by Laurie Leary and John Leary on behalf of Sean Leary, de-
ceased, in the United States Court of Federal Claims as required under the National Vaccine
Injury Compensation Program. Id. at 1. The government declined to concede the case on its
pleadings arguing an alternative cause of Sean's death (myocarditis of viral origin). Id. A spe-
cial master subsequently found for the petitioners. Id.
12. Id. at *6. Contrary to Dr. Klein's testimony, the court held for the petitioners, the
Learys. Id.
13. http://pneumo.comhome.html (last visited October 12,2000).
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also manufactures eight other vaccines. 4 Besides having a relationship with
this major vaccine manufacturer, Dr. Klein holds a position on the National
Vaccine Advisory Committee. This committee helps the federal government
decide what vaccines will be recommended for all children in the United
States.'s
One of Dr. Klein's colleagues is James Cherry, M.D. Dr. Cherry has
been called "the leading defense expert witness in vaccine litigation."' 6 By
1988, Cherry had testified in over eighty cases in which parents sued be-
cause their children were allegedly injured or killed by vaccines. 7 Cherry
has written that it is a "myth" that pertussis vaccination can cause encepha-
lopathy (brain inflammation) 8, even though a manufacturer lists it under ad-
verse reactions. 9 Furthermore, Cherry has financial relationships with at
least four major vaccine manufacturers."0 One manufacturer, Wyeth-Lederle,
has paid his department at UCLA Medical Center $450,000 in unrestricted
funds labeled as "gifts."' But most importantly, Cherry has been a member
of the Center for Disease Control and Prevention's Advisory Committee on
Immunization Practices (ACIP)Y This committee plays a key role in deter-
mining U.S. vaccination policy by making vaccine recommendations to the
Director of the Centers for Disease Control and Prevention (CDC).'
14. Michael R. Hugo, Vaccine Manufacturers and Breast Implant Manufacturers: Same
Game, Same Strategies. A Mere Coincidence?, The Consumer Law Page, October 26, 1996,
at http://consumerlawpage.com/article/vaccine.shtml. See also PHYSICIANS' DESK REFERENCE
208 (51' ed. 1997) [hereinafter PDR 51]. Lederle manufacturers nine vaccines as of 1997. Id.
15. NATIONAL VACCINE ADVISORY COMMITTEE, ADULT IMMUNIZATION PROGRAMS IN
NONTRADrrIONAL SETTINGS: QUALITY STANDARDS AND GUIDANCE FOR PROGRAM
EvALUATION (2000), http:llwww.cdc.gov/epo/mmwr/preview/mmwrhtml/rr4901 al.htm
(committee membership list).
16. Hugo, supra note 14.
17. Callahan v. Cardinal Glennon Hosp., 863 S.W.2d 852, 869 (Mo. 1993).
From his testimony it was revealed that financial assistance for Dr. Cherry's de-
partment and research came through large grants from Lederle. It was also re-
vealed that Dr. Cherry testified for Lederle and other similar companies against
plaintiffs in eighty to one hundred products liability or medical malpractice ac-
tions.
Il
18. James Cherry, 'Pertussis Vaccine Encephalopathy': It Is Time to Recognize It as the
Myth that It Is, 263 JAMA, 1679 (1990).
19. "Neurological complications, such as convulsions, encephalopathy and various
mono- and polyneuropathies, including Guillain-Barre syndrome have been reported follow-
ing administration of preparations containing diphtheria, tetanus, and/or pertussis antigens."
PDR 51, supra note 14, at 1417.
20. Hugo, supra note 14.
21. See id. According to Hugo, "This was so designated to allow Dr. Cherry free access
to more of the money." Il
22. HARIS L. COULTER & BARBARA LOE FISHER, A SHOT IN THE DARK 182 (1991). An-
drea Rock, The Lethal Dangers of the Billion-Dollar Vaccine Business, MONEY MAGAZINE,
Dec. 1996 at 148, http://www.geocities.com/Heartland/Flats/6997.
23. FACA: Conflicts of Interest and Vaccine Development: Preserving the Integrity o(
the Process, Before the Government Reform Committee of the House of Representatives, 106
2
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Our legal system entitles pharmaceutical companies to hire expert wit-
nesses to defend their products in court. But a growing number of people
who are concerned with the safety of vaccines are fearful that these relation-
ships are jeopardizing the integrity of vaccine policymaking.24 They ascribe
their concern to the fact that many of the doctors who enjoy financial con-
nections with vaccine manufacturers are the same individuals who sit on
federal advisory committees and make vaccine policy for the country.'
Sean Leary is not alone. Since 1986 there have been over 5,000 claims
alleging serious childhood vaccine injury 6 including death, paralysis, seizure
disorders, and epilepsy.27 And these claims may represent just a fraction of
the total number of injuries.28 New vaccines are also bringing new injuries.
In March 1999, a vaccine was approved that was designed to prevent diar-
rhea.2" Within four months it had killed at least one child and critically in-
jured nearly a hundred more by causing intussusception,0 a previously rare
Cong. (June 15, 2000) [hereinafter Conflicts of Interest and Vaccine Development] (statement
of Dixie E. Snider, MD, MPH, Associate Director of Science, Centers for Disease Control
and Prevention (June 14, 2000) at http:lwww.house.gov/reformlhearingslhealthcare/
00.06.15/snider.htm.
The ACIP provides advice and guidance to the Secretary, Department of Health
and Human Services (HHS), the Assistant Secretary for Health, and the CDC Di-
rector on the most effective means to prevent vaccine-preventable diseases. The
ACIP develops written recommendations, subject to the approval of the CDC Di-
rector, for the routine administration of vaccines for the pediatric and adult popula-
tions, along with schedules regarding the appropriate periodicity, dosage, and con-
traindications applicable to the vaccines. In addition, as provided by statute, the
ACIP designates vaccines for administration in the Vaccines for Children Program
(VFC)... The overall goal of the ACIP is to provide advice that assists CDC, HHS
and the Nation in reducing new cases of vaccine preventable diseases and increas-





26. Edmund W. Kitch et al., U.S. Law, in VACCINES 1175 (Stanley A. Plotkin & Walter
A. Orenstein eds., 3d ed. 1999).
27. Vaccine Adverse Event Reporting System Searchable Database, at
http://www.fedbuzz.comvaccine/vac.html (last visited October 18, 2000).
28. See generally Kitch, supra note 26, at 1170. Each injury brought in the Court of Fed-
eral Claims should be found listed on the vaccine in table. IL at 1174-5. The burden of proof
is the preponderance of the evidence. Id. If the injury is not on the table, then the burden is
proving causation. Id. The parameters for the table injuries are strict, i.e. encephalopathy must
happen within 72 hours and the table excludes more injuries than it includes when compared
to the package inserts. Id. See also National Vaccine Information Center, at
http://www.909shot.com/gnscompe.htm, (last visited Oct. 29, 2000). "I think the vaccine pro-
gram is an abysmal failure. It is an uncertain, slow, horrible system that is broken." Hugo, su-
pra note 14.
29. MAJORITY STAFF OF THE COMM. ON GOVERNMENT REFORM, U.S. HOUSE OF REP.,
1O6 CONG., CONFLICTS OF INTEREST IN VACCINE POLICY MAKING 9 (Aug. 21, 2000) [herein-
after MAJORITY STAFF REPORT].
30. DORLAND'S ILLUSTRATED MEDICAL DICTIONARY 794 (2 5' ed. 1974). Intussusception
3
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disease.' Three months later it was withdrawn from the market."
The House of Representatives Government Reform Committee con-
ducted an investigation into the background of the doctors who participated
in the pivotal FDA and CDC vaccine advisory committees that allowed this
vaccine to be approved. The investigation culminated in a committee report
released on August 21, 2000."3 According to the report, "The Committee's
investigation has determined that conflict of interest rules employed by the
FDA and CDC have been weak, enforcement has been lax, and committee
members with substantial ties to the pharmaceutical companies have been
given waivers to participate in committee meetings."
Vaccines are the only medical intervention mandated for healthy chil-
dren.35 Although some exemptions are possible36, children may not be
permitted to attend public school and their parents can be charged with
neglect or child abuse, if the child is not vaccinated." Parents must therefore
rely upon the integrity of federal vaccine policymaking. Their children's
lives depend on the exercise of careful and prudent decision making devoid
of self-interest. The increasing numbers of vaccine injuries and the
revelations of the Congressional Investigation raise an important question-
how can the law provide children with safe, effective and necessary vaccines
when the current system cannot adequately police conflicts of interest and
children are obligated to get their shots?
Every child in this country is vulnerable to a system that places financial
ties before human life. This note will argue that the pharmaceutical compa-
nies play a key role in determining what will be injected into healthy chil-
dren. It will suggest that this involvement has resulted in the expenditure of
millions of dollars for vaccines that may be unnecessary or unsafe. Various
solutions will be presented, each designed to protect children's lives.
is a disease in which the intestine collapses into itself-"the prolapse of one part of the intes-
tine into the lumen of an immediately adjoining part." Id.
31. "[Prior to the release of RotaShield], on January 1, 1999 there were zero cases of in-
tussusception in the Vaccine Adverse Events Reporting System (VAERS)." MAJORITY STAFF
REPORT, supra note 29, at 10.
32. ld.
33. Id.
34. Id. at 16.
35. See Kristine M. Severyn, Jacobson v. Massachusetts: Impact on Informed Consent
and Vaccine Policy, Journal of Pharmacy and Law, 5 JPHARML 249, 250 (1996). See also
Robert T. Chen, Safety of Vaccines, in VACCINES, supra note 26, at 1145. A higher standard
of safety is expected with vaccines in comparison to other medical interventions because vac-
cines are compulsory. Id.
36. A State-by-State Summary of Vaccine Exemptions at http://www.tetrahedron.org
/news/contacts.html, (last visited Oct. 29, 2000). All states, except Mississippi and Virginia
permit religious exemptions and philosophical exemptions are available in approximately half
of the states. Severyn, supra note 35, at 260.
37. Severyn, supra note 35, at 259. Severyn discusses In the Matter of Christine M., 595
N.Y.S.2d 606, 607 (N.Y. Fam. Ct., 1992) in which a three-year old child was considered "ne-
glected" by the authorities because the parent refused a measles vaccine. Id.
(Vol. 37
4
California Western Law Review, Vol. 37 [2000], No. 2, Art. 4
https://scholarlycommons.law.cwsl.edu/cwlr/vol37/iss2/4
2001] ENSURING SAFE, EFFECTIVE AND NECESSARY VACCINES 325
Section I discusses the fact that children are now getting more vaccines
at a younger age than ever before. It highlights the concerns of physicians,
scientists, and parents, and presents information from federal databases and
the medical literature. Section II examines the conflicts of interests uncov-
ered in vaccine policymaking. It provides a brief review of the findings of a
recent congressional investigation on the most influential vaccine commit-
tees: the FDA's Vaccines and Related Biological Products Advisory Com-
mittee (VRBPAC) and the Centers for Disease Control and Prevention's
Advisory Committee on Immunization Practices (ACIP). It also highlights
the conflicts of interest associated with the two newest childhood vaccines,
RotaShield and Prevnar. Section III will examine various solutions to rees-
tablish integrity in vaccine policymaking, and how children can be protected
from abuses. Two different categories of solutions will be offered. The first
focuses on strategies to eliminate, reduce, or compensate for conflicts of in-
terest in vaccine policymaking. Various approaches will be discussed, in-
cluding closing the loopholes in the current law, instituting a more stringent
code of ethics, retooling the committees, and adding an oversight or om-
budsman role. The second category of solutions takes a remedial perspective
and focuses both on protecting children and punishing those who abuse the
system. These approaches include utilizing taxpayer derivative actions to in-
duce state agencies to scrutinize federal vaccine recommendations and using
Qui Tam litigation under the False Claims Act to encourage manufacturers
to reform their vaccine manufacturing and marketing strategies. Section IV
will seek to redefine the problem by taking a preventive law approach. Here,
the current paradigm, a vaccine for every ill, will be challenged. 8 Finally,
Section V will provide some concluding thoughts on the steps required to
facilitate positive change.
I. MORE VACCINES FOR YOUNGER CHILDREN
A. Thirty Vaccines in Eighteen Months
My parents were born in the 1930s. Members of their generation re-
38. E-mail from Barbara Loe Fisher, President of the National Vaccine Information Cen-
ter. Ms. Fisher has served on the National Vaccine Advisory Committee (1988-1991), the In-
stitute of Medicine Vaccine Safety Forum (1995-1998), and voting consumer member, FDA
Vaccines and Related Biological Products Advisory Committee (1999-present) (Oct. 9, 2000)
(on file with author).
[Policymakers] see their mission as eradicating most, if not all, infectious microor-
ganisms from the earth. So when drug companies produce a new vaccine that is, in
effect, a new weapon in their war on infectious microorganisms, they want every-
one to use it. In their minds, the benefits of using this new weapon to achieve their
mission always outweighs the risks associated with its use.
5
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ceived three vaccines.39 I was born in the early 1960s and received vaccines
for polio, smallpox and DPT.' A child born today will receive five doses of
DPT, four doses of polio vaccine, two doses of measles, mumps and rubella,
three injections of hepatitis B, one shot of varicella (chicken pox), four doses
of haemophilus influenzae b (Hib), four injections of a pneumococcal conju-
gate vaccine, and, depending on where the child lives, perhaps one shot of
hepatitis A.4' In addition to getting more shots, children today get vaccines at
a younger age. As displayed infra, twenty of the twenty-four injections
(thirty of the thirty-eight different constituent vaccines)42 should be adminis-
tered to a child before he or she is eighteen months old.43 In addition, some
children may also be injected with up to nine different vaccines in a single
day.44
39. Kathy Koch, Vaccine Controversies, 10 CQ RESEARCHER 644 (2000).
40. Id.
41. See American Academy of Pediatrics, American Academy of Pediatrics 2000 Immu-
nization Schedule, at http:llwww.aap.orglfamily/parents/immunize.htm, (last visited October
20, 2000) (lists all the vaccines except pneumococcal conjugate vaccine). See also American
Academy of Pediatrics, AAP Recommends Pneumococcal Vaccine for Children Under Age 2
at http:llwww.aap.oigladvocacy/archives/junpcv7.htm, (last visited October 20, 2000) (adds
pneumococcal vaccine to schedule).
42. For example, one dose of Measles-Mumps-Rubella (MMR) is combined in one shot.
However, if one were to count the actual vaccine constituents (i.e. one dose of MMR is
equivalent to three, one for Measles, one for Mumps, one for Rubella) then the number of
separate injections translate into thirty-eight vaccines of which thirty are administered before
a child is eighteen months old.
43. Recommended Childhood Immunization Schedule United States, January - December
2001 is approved by the Advisory Committee on Immunization Practices (ACIP), the Ameri-
can Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP).
Please note that the schedule reproduced in this article does not contain the full directions to
clinical practitioners nor does it include the footnoted annotations that provide additional in-
formation. Therefore this schedule should not be used to replace an actual schedule provided
by the CDC, AAP or AAFP. See http:llwww.aap.orglfamily/parents/immunize.htm.
44. Autism: Present Challenges, Future Needs-Why the Increased Rates? Before the
Government Reform Committee of the House of Representatives, 10 6 ' Cong. (April 6, 2000)[hereinafter Autism Hearings] (opening statement of Chairman Dan Burton) at
http:llwww.house.gov/reform/hearings/healthcare/00.06.04'opening-statement.htm. "[My
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Recommended Childhood Immunization Schedule
United States, January - December 2001
Childhood vaccination has been considered one of the leading public
Agep gkh 1 2 4 6 12 15 1S 24 " 13-12 14-l1
Vacdnet ..... mot Mot Me Mo ms ',1
Hepatitis B
H ep Hep B i
Diphtheria,
Tetanus, DT.P DT-P DTaP DTaP DTaP TI
Pertussis
H. ialuenme Hill Hib Hib H
typeb
Inactivated IPV WPV IPV IPV
Polio





Hepatitis A Hep-AI selected areas
Appreve I ky Adsry Co itPeeicxtc (ACIP),tI.. Atmrdc aA Axy eyPef.trlt cs(AAP)6mdie
Ame-i eAssdey offamly Pk.sklua (AAFP).
health measures of the twentieth and twenty-first centuries. 5 Vaccines have
been credited with controlling dangerous diseases and reducing the associ-
ated mortality and morbidity. ' Nonetheless, there is a growing number of
physicians, scientists and parents who strongly believe that the increasing
numbers of these unavoidably unsafe products47 administered at younger
45. INSTITUTE OF MEDICINE, ADVERSE EVENTS ASSOCIATED WITH CHILDHOOD VACCINES:
EVIDENCE BEARING ON CAUSALITY 1 (Kathleen R. Stratton et al. eds., National Academy Press
1994).
46. Susan L. Plotkin & Stanley A. Plotkin, A Short History of Vaccination, in VACCINES,
supra note 26, at 1.
47. Severyn, supra note 35, at 267 (citing THE RESTATEMENT (SECOND) OF TORTS §
402A comment k (1965)); 'There are some products which, in the present state of human
knowledge, are quite incapable of being made safe for their intended and ordinary use. These
are especially common in the field of drugs... The seller of such products, again with the
qualification that they are properly prepared and marketed, and proper warning is given,
where the situation calls for it, is not to be held to strict liability for unfortunate consequences
attending their use, merely because he [she] has undertaken to supply the public with an ap-
parently useful and desirable product, attended with a known but apparently reasonable
risk.").
7
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ages are damaging and sometimes killing healthy children."8
In the 1970s and early 1980s, the number of lawsuits and the size of
damage awards for vaccine injury grew at an alarming rate. The response
from manufacturers was to encourage lawmakers to pass the National Child-
hood Vaccine Injury Act.' This Act, passed in 1986, requires that all vaccine
injuries first be brought forward in the Federal Court of Claims." Only after
such a claim is filed and the plaintiff is unhappy with the result can a civil
action be filed.5" The Act insulated manufacturers from tort liability and put
a cap on monetary damages of $250,000 when a child dies from a vaccine
injury. 3 Additionally, it created an excise tax on every vaccine that finances
a fund that is used to pay damage awards so that vaccine manufacturers are
not held financially liable.'
In addition to providing a fund to compensate victims of vaccine injury,
the Act also called for the creation of the Vaccine Adverse Events Reporting
System (VAERS).55 This reporting system requires that health care providers
report selected adverse events occurring after vaccination 6 Because this is a
passive system, only a "fraction" of events are thought to be reported. Seri-
ous adverse events, however, are considered to be accurately diagnosed 8
48. See infra note 72 and accompanying text.
49. See generally Kitch, supra note 26, at 1168-69.
50. See Severyn, supra note 35, at 261-62.
51. Id.
52. 42 U.S.C. § 300aa (2000) (The National Childhood Vaccine Injury Act was enacted
in 1986). 42 U.S.C. § 300aa-1 1(a) states in part:
(2)(A) No person may bring a civil action for damages in an amount greater than
$1,000 or in an unspecified amount against a vaccine administrator or manufac-
turer in a State or Federal court for damages arising from a vaccine- related injury
or death associated with the administration of a vaccine after the effective date of
this subpart, and no such court may award damages in an amount greater than
$1,000 in a civil action for damages for such a vaccine- related injury or death,
unless a petition has been filed, in accordance with section 300aa-16 of this title,
for compensation under the Program for such injury or death.
53. Kitch, supra note 26, at 1174. See also Childhood Vaccine Excise Tax Reduction to
25 per dose Recommended, 59 (No. 51) THE PINK SHEET 5 (1997) ("In general, the vaccine
manufacturers' risk of liability has decreased since the inception of the VICP [Vaccine Injury
Compensation Program] of 1988 according to a survey by the Office of the General Coun-
sel."); Lederle-Praxis DTP Vaccine Price Drops 52% Due to Decreased Liability, 52 (No.
49); Tim PINK SHEET (1990) (Claims for injuries allegedly resulting from Lederle's DTP went
from 255 complaints in 1986 to only 50 in 1989 and approximately 25 in 1990.).
54. Rebecca Porter, Vaccine Injury Compensation Reaches Nearly $1 Billion, TRIAL,
Dec. 1998, at 99.
55. Kitch, supra note 26, at 1170.
56. Severyn supra note 35, at 267.
57. See David A. Kessler, Introducing MedWatch: A New Approach to Reporiing Medi-
cation and Device Adverse Effects and Product Problems, 269 JAMA 2765 (June 2, 1993).
This former commissioner of the FDA has written that "only - fraction" of serious adverse
events are reported to the FDA." Id.
58. Chen, supra note 35, at 1151.
[Vol. 37
8
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Even with the presumed underreporting, there are over 108,000 reports of
adverse reactions and death allegedly resulting from vaccination amassing in
the VAERS database.59
C. The Medical Literature
The medical literature provides evidence that vaccines may be danger-
ous to some children.' The possibility that vaccines can cause neurological
complications in children was recognized as early as 19191 when "amyotro-
phic paralysis and polyneuritis were definitely recognized as complications
[of vaccination]."" Since that time several hundred medical studies have re-*
ported a variety of severe neurological complications associated with vacci-
nation.' These complications have included: encephalitis, myelitis, Guillain-
59. Vaccine Adverse Event Reporting System, Frequently Asked Questions About
VAERS, What is VAERS?, http://www.vaers.net/vaers.htm, (Data from 1986 to the present)
(last visited October 15, 2000). The following examples are from the Vaccine Adverse Event
Reporting System Searchable Database, at http://www.fedbuzz.com/vaccine/vac.html, (last
visited October 18, 2000): A healthy baby boy was vaccinated with DTP on December 10,
1997. Four days later he had a fever and became weak. The following day his temperature
increased. He had convulsions and difficulty breathing. He was rushed to the hospital and
died two days later. Another baby boy was administered the measles, mumps and rubella vac-
cine. Following the vaccination the child had encephalitis (inflammation of the brain) and was
hospitalized. The child died a short time later. A biopsy revealed the presence of "measles
inclusion bodies" in the brain. A nine-year old boy received the hepatitis B vaccine and soon
developed tics. Later, when he was administered a booster shot the tics became worse and the
child was ultimately diagnosed with Tourette's disease. Two weeks after another apparently
healthy infant was vaccinated she was taken to the doctor because her foot dropped and her
ribs were pulled inward. One week later she stopped eating. She was rushed to the ER in car-
diopulmonary arrest. There she was revived and diagnosed with muscular dystrophy. Soon
after a healthy five-year old boy was vaccinated with diphtheria and tetanus he had nausea,
vomiting and fever as high as 103 degrees for three days. He was unable to smile. He was
taken to the doctor and subsequently diagnosed with Bell's Palsy.
60. In Congressional testimony, Marcel Kinsboume, M.D. summarized three ways that a
vaccine may be harmful to some children including:
[I] Toxic: Killed bacteria [in vaccines] may release toxins when their cell bodies
break down... [2] Infectious: A vaccine that consists of attenuated virus particles
may cause the very infection it was intended to prevent... [3] Autoinmune: The
body responds to a vaccine with an immune reaction that also attacks a constituent
of the body which bears some chemical resemblance to a constituent of the vac-
cine.
Vaccines: Public Safety and Personal Choice Before the Government Reform Committee of
the House of Representatives, 106' Cong. [hereinafter Vaccines: Public Safety and Personal
Choice] (statement of Marcel Kinsbourne, M.D.) (Aug. 3, 1999) at
http://www.house.govlreformlhearingslhealthcare/99.08.03/kinsboume.htm. See generally
VIERA SCHEIBNER, VACCINATION: 100 YEARS OF ORTHODOX RESEARCH SHOWS THAT
VACCINES REPRESENT A MEDICAL ASSAULT ON THE IMMUNE SYSTEM (1993).
61. Henry G. Miller & John B. Stanton, Neurological Prophylactic Inoculation, 23 Q. J.
MED. 1, 2 (1954).
62. Id.
63. Various neurological complications including encephalitis, myelitis, Guillain-Barre
syndrome, radicular, polyneuritic and mononeuritic syndromes were associated with vaccina-
9
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Barre syndrome, radicular, polyneuritic and mononeuritic syndromes, Reye
syndrome (which has a 50% mortality rate"), and encephalopathy.'
In addition to permanent and severe neurological reactions, some scien-
fists are studying how vaccines may be responsible for the tremendous in-
crease in autoimmune diseases.' In 1967, a paper was published in the Brit-
ish Medical Journal that suggested three possible methods in which various
vaccines could cause or contribute to multiple sclerosis in children and
adults including: introducing a viral organism, triggering a latent condition
or causing the disease by itself.7 A study in New Zealand found that vacci-
nated children had a 23% rate of asthma episodes and a 30% rate for consul-
tations for other allergic diseases.' However unvaccinated children had a 0%
rate for both allergies and asthma.' On-going studies in Europe and the U.S.
have found a possible correlation between the measles vaccine and subse-
quent Crohn's disease. In addition, autism rates have risen dramatically. In
California, the rate has increased 210% from 1987 to 1998." Scientists,
tion in 1954. See id at 24. A 1977 study conducted by the UCLA School of Medicine found
that Guillain-Barre syndrome could follow a tetanus-diphtheria vaccination. R. Bdkashi and
MC Graves, Guillain-Barre Syndrome After Combined Tetanus-Diphtheria Toxoid Vaccina-
tion, 147(2) J. NEUROLOGICAL Sci. 201 (1977). A 1979 study found that vaccination with live
virus vaccines (i.e. measles, mumps, rubella, oral polio), "may occasionally serve as cofactors
in the etiology of Reye syndrome through undefined mechanisms." David M. Morens, M.D.
et al, Reye Syndrome Associated with Vaccination with Live Virus Vaccines, 18 CLINICAL
PEDIARuCS 42 (1979). Reye's syndrome has a mortality rate of approximately 50%. See infra
note 64. In a 1983 letter to the medical journal The Lancet, Dr. Gordon Stewart drew attention
to a British study that demonstrated a small but statistically significant number of temporary
and permanent neurological disorders related to the pertussis vaccine. Gordon T. Stewart Re-
actions to Pertussis Vaccine, LANCET, May 28, 1983, at 1217-18. In 1985, Science reported
that, "Encephalitis, myelitis, and neuritis are well-known complications of certain viral infec-
tions and vaccines. .. "See Ulrike Jahnke et al., Sequence Homology Between Certain Viral
Proteins and Proteins Related to Encephalomyelitis and Neuritis, SCIENCE, July 19, 1985, In
1991, a report released by the Institute of Medicine found "a possible causal relation between
DTP vaccine and acute encephalopathy." See L.D. Cowan et al., Acute Encephalopathy and
Chronic Neurological Damage After Pertussis Vaccine, 14 VACCINE 1371 (1993).
64. Reyes syndrome is characterized by vomiting followed by stupor which progresses to
generalized convulsions and coma. Kurt J. Isselbacher & Daniel K. Podolsky, Infiltrative and
Metabolic Diseases Affecting the Liver, in HARRISON'S PRINCIPLES OF INTERNAL MEDICINE, pt.
11 § 2, at 1719 (Anthony S. Fauci, M.D. et al., eds, 14th ed 1998). The mortality rate is 50%.
65. See Kitch, supra note 26, at 1170.
66. See generally Autism Hearings, supra note 44 (statements of Vijendra K. Singh,
Ph.D., Andrew Wakefield, MD) at http://www.house.gov/reform/hearings/healthcare
/00.06.04/index.htm.
67. Henry Miller et al., Multiple Sclerosis and Vaccination, BRIT. MED. J., 212 (1967).
68. T. Kemp et al., Is Infant Immunization a Risk factor for Childhood Asthma or Al-
lergy?, 8 EPIDEMIOLOGY, 678 (1997).
69. lId
70. Andrew Wakefield, et al., Perinatal Measles Infection and Subsequent Crohn's Dis-
ease, LANCET, Aug. 20, 1994, at 508; Autism Hearings (statement of Vijendra K. Singh,
Ph.D.) supra note 66. See also R. Ray et al., Direct In Situ Transcriptase Polymerase Chain
Reaction in Detection of Measles Virus, J. VIROLOGICAL METHODS, 1 (1996).
71. California Health and Human Services Agency, Department of Developmental Ser-
330 [Vol. 37
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medical doctors and parents have testified before Congress that they believe
vaccines are responsible for the increase.72
Even Sudden Infant Death Syndrome (SIDS) has been associated with
vaccination by a very small number of physicians and scientists. 3 In 1982 a
presentation was made in Dallas, Texas at the "Session on Child Neurology"
in which Dr. William Torch reported his findings related to DPT vaccination
and SIDS.7 He wrote, "In conclusion, these data show that DPT vaccination
may be a generally unrecognized major cause of sudden infant and early
childhood death, and that the risks of immunization may outweigh its poten-
tial benefits." ' A year later, Dr. L. Baraff et al. studied SIDS death in Los
vices, Changes in the Population of Persons with Autism and Pervasive Developmental Dis-
orders in California's Developmental Services System: 1987 through 1998, March 1, 1999, at
7.
72. For example of scientists see Autism Hearings, supra note 44 (statement of Vijendra
K. Singh, Ph.D., Department of Biology & Biotechnology Center, Utah State University) at
http://www.house.gov/reform/hearings/healthcare/0O.06.04/singh.htm ("the data will lead to
inescapable conclusion that these vaccines can potentially cause autoimmunity in autism.");
Mercury in Medicine: Are We Taking Unnecessary Risks? Before the Government Reform
Committee of the House of Representatives [hereinafter Mercury Hearings], 106' Cong. (July
18, 2000) (statement of Stephanie Cave, MD) at http:llwww.house.gov/reform
/hearings/healthcare/00.07.18/cave.pdf. ("I believe that the introduction of the Hepatitis B
vaccine in 1991 has sparked this recent epidemic [of autism] because of the thimerosal [form
of mercury]."). For an example of a parent see Autism Hearings (statement of Congressman
Dan Burton) supra note 44
(I don't have to read a letter to experience the heartbreak. I see it in my own fam-
ily. My grandson Christian was born healthy. He was beautiful and tall. We were
already planning his NBA career. He was outgoing and talkative. He enjoyed
company and going places. Then, his mother took him for his routine immuniza-
tions and all of that changed. He was given what so many children were given-
DTaP, OPV, Haemophilus, Hepatitis B, and MMR-all at one office visit. That
night Christian had a slight fever and he slept for long periods of time. When he
was awake he would scream a horrible high-pitched scream. He would scream for
hours. He began dragging his head on the furniture and banging it repeatedly. Over
the week-and-a-half after the vaccinations, Christian would stare into space and act
like he was deaf. He would hit himself and others, which was something he had
never done. He would shake his head from side to side as fast as he could. He lost
all language. [He has subsequently been diagnosed as autistic]).
73. William C. Torch, Diphtheria-Pertussis-Tetanus (DPT) Immunization: A Potential
Cause of the Sudden Infant Death Syndrome (SIDS), 32 NEUROLOGY A169 (1982); Baraff LJ,
et al., Possible Temporal Association Between Diphtheria-Tetanus Toxoid-Pertussis Vaccina-
tion and Sudden Infant Death Syndrome, 2(1) PEDIATRIC INFEcTIous DIsEAsEs 7-11 (1983);
Bernier RH, et al., Diphtheria-Tetanus Toxoids-Pertussis Vaccination and Sudden Infant
Deaths in Tennessee, 101(3) J. PEDIATRIcS 419-21 (1982). SCHEIBNER, supra note 60, at 13-
71.
74. Torch, supra note 73. Dr. Torch's study was inspired by reports of eight DPT-
associated SIDS in Tennessee and four SIDS within 3 / to 19 hours of inoculation in Nevada.
Id. Subsequent to these reports, Dr. Torch analyzed 200 randomly selected SIDS cases. Id. He
found that "6.5% died within 12 hours of inoculation; 13% [died] within 24 hours; 26% [died]
within 3 days, and 37%, 61%, and 70% within 1, 2, and 3 weeks, respectively." Id. Dr. Torch
was formerly Director of Child Neurology, Department of Pediatrics, at the University of Ne-
vada School of Medicine. Id.
75. Id.
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Angeles and concluded that 'These SIDS deaths were significantly more
than expected were there no association between DTP immunization and
SIDS." 6 Although other studies have not found any association between
vaccination and SIDS, the fact that results have been inconsistent between
studies is disturbing to some scientists.n
The numerous warnings and adverse events reported in the manufac-
turer's inserts that accompany each vaccine also raise concerns.7 ' These in-
serts are careful to draw a distinction between adverse events caused by the
vaccine and those merely associated with the vaccine .7 One reason for this
distinction is the lack of studies undertaken on causation."0 According to a
1994 Institute of Medicine review of adverse events associated with child-
hood vaccines, "[During the review], the committee encountered many gaps
and limitations in knowledge bearing directly and indirectly on the safety of
vaccines."8' Even with this gap, the inserts list a number of dangerous and
deadly adverse reactions associated with vaccines, including: neurological
complications, convulsions, encephalopathy (degenerative disease of the
brain), shock, apnea, Guillain-Barre Syndrome (nerve inflammation), col-
lapse, orchitis (inflammation of the testes), abnormal liver function, Bell's
Palsy, multiple sclerosis and SIDS.'
D. Carcinogens and Toxins in the Vaccines
Concerned scientists and physicians are trying to discern the biological
mechanisms that explain how vaccines can cause these injuries or deaths.83
76. Baraff LJ, et al., Possible Temporal Association Between Diphtheria-Tetanus Tox-
oid-Pertussis Vaccination and Sudden Infant Death Syndrome, 2(1) PEDIATRIC INFECTIOUS
DIsEAsEs 7-11 (1983).
77. See SCHEIBNER, supra note 60, at 13-71.
78. The adverse reactions listed for Acel-Imune-the acellular DTP vaccine manufac-
tured by Lederle-include: vomiting, anaphylactic reactions (i.e. difficulty breathing, shock)
neurological complications, convulsions, and encephalopathy (degenerative disease of the
brain). PDR 51, supra note 14, at 1415-17. Adverse reactions listed for Smith Kline's DTP
includes: shock, apnea (breathing stops), anorexia, vomiting, convulsions, encephalopathy
(degenerative disease of the brain), Guillain-Barre Syndrome (nerve inflammation), collapse,
and SIDS ("Sudden Infant Death Syndrome has occurred in infants following administration
of DTP."). See id. at 2650-53. Adverse reactions listed for SmithKline's hepatitis B vaccine
("Engerix") includes: Tinnitus (ringing in ears), earache, vomiting insomnia, tachycar-
dia/palpitations (rapid heart beat), abnormal liver function, Guillain-Barre Syndrome (nerve
inflammation), Bell's Palsy, and multiple sclerosis. See id. at 2656-58.
79. See generally INSTrUTE OF MEDICINE, supra note 45, at 5, 17, 317.
80. Id.
81. Id. at 317.
82. See, e.g., Pneumoccocal 7-vaent Conjugate Vaccine (Diphtheria CRMW Protein)
Package Insert [hereinafter Package Insert] at http://www.pneumo.com/vaccine/PI.html (last
visited on Sept. 13, 2000).
83. See Autism Hearings (statements of Vijendra K. Singh, Ph.D., Mary Megson M.D.,
Bernard Rimand, Ph.D.) at http:llwww.house.gov/reform/hearings/healthcare /00.04.06/ in-
dex.htm.; Harold Buttram, M.D., Vaccine Scene 1999: Overview And Update, at
http:llwww.whale.to/vaccines/buttraml.htm (last visited February 17, 2001); National Vac-
[Vol. 37
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Some have concluded that the mercury used as a preservative in many vac-
cines needs to be eliminated." Dr. Vasken Aposhian, an expert in molecular
and cellular biology, has testified, "I am rather amazed that [mercury] has
been a constituent of vaccines for children. There is no need of endangering
any child with any form of mercury. Many countries... have banned [its]
use. . ."' In fact, according to the congressional testimony of one medical
doctor, the two-month dose of mercury a child is exposed to through vac-
cines, "is at least 30 times higher than the recommended daily maximum ex-
posure as set by the EPA."'
In addition, to mercury, the dissolved aluminum in vaccines is also po-
tentially dangerous. According to the journal Pediatrics, "[a]luminum is now
being implicated as interfering with a variety of cellular and metabolic proc-
esses in the nervous system and in other tissues."" There are other ingredi-
ents that raise concerns that are either in the shots themselves or used in the
manufacturing process. These substances include: formalin (a type of for-
maldehyde), monkey kidney cells, human fetal tissue (from abortions), pig
enzymes, sheep red blood cells, calf serum, yeast, fetal cow serum, chicken
embryos, ammonium sulfate, and monosodium. glutamate.88
E. Are All These Vaccines Necessary?
Given the potential danger of vaccine ingredients and the association
between vaccination and injury cited in the medical literature, critics chal-
lenge the necessity of some vaccines especially when they are designed to
prevent diseases that children are not at risk for or are not dangerous. For ex-
ample, the chicken pox vaccine is targeted against a "disease" that is very
seldom dangerous or deadly.89 The rotavirus vaccine is designed to prevent a
virus that causes diarrhea, takes the lives of approximately twenty children
cine Information Center, Professor of Cell Biology Investigates Hep B Vaccine Damage at
http://www.909shot.com/profcellbio.htm (last visited February 17, 2001) (discussing the re-
search by Professor Bonnie Dunbar, Ph.D. into the adverse effects caused by the hepatitis B
vaccine); R. Riikonen, The Role of Infection and vaccination in the Genesis of Optic Neuritis
and Multiple Sclerosis in Children, 80(5) ACTA NEUROL SCAND 425-31 (1989).
84. Mercury Hearings, supra note 72 (statement of H. Vasken Aposhian, Ph.D, Professor
of Molecular and Cellular Biology, The University of Arizona) at http://www.house.gov
/reform/hearings/healthcareaposhian.pdf; (statement of Stephanie Cave, MD), supra note 72
(Dr. Cave's testimony also lists the 17 vaccines currently containing mercury).
85. Mercury Hearings (statement of H. Vasken Aposhian), supra note 84.
86. Mercury Hearings (statement of Stephanie Cave), supra note 72.
87. Aluminum Toxicity in Infants and Children (RE9607), 97 PEbIATRIcs 413,
http://www.aap.org/policy/0l1263.html, (last visited Sept. 14, 2000). The amount of aluminum
in those vaccines that contain it can be as high as .85 mg per 0.5mL dose. See, e.g., Acel-
Imune manufactured by Lederle Laboratories. PDR51, supra note 14, at 1415.
88. See generally PDR 51, supra note 14.
89. "In the immunocompetent patient, [chickenpox] is usually a benign illness. . ." Rich-
ard J. Whitley, Varicella-Zoster Virus Infections, in, HARRISON'S PRINCIPLES OF INTERNAL
MEDICINE, supra note 64, pt. 7 § 185, at 1086.
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per year in the United States,' and is no more than a sub-clinical infection9
in the overwhelming majority of America's 19 million children under the
age of five.' Those at risk for hepatitis B include adults who share intrave-
nous needles, engage in promiscuous unprotected sex, and health care work-
ers.93 Yet, children who do not fit into these categories, receive three hepati-
tis B vaccinations before they are eighteen months old.94 Concerned parents
have asserted that the number of deaths and injuries caused by this vaccine
may be more than the deaths and injuries caused by the illness that the vac-
cine is designed to prevent."' Some physicians and scientists have also chal-
lenged the risk-benefit equation for this particular vaccine.96
90. Conflicts of Interest and Vaccine Development (oral testimony of Dixie E. Snider,
MD, MPH, Associate Director of Science, Centers for Disease Control and Prevention), supra
note 23, at transcript lines 2616 ("[There are approximately] only 20 deaths from rotavirus in
the United States."); Centers for Disease Control, Rotavirus Vaccine for the Prevention of Ro-
taviris Gastroenteritis Among Children, MMWR March 19, 1999, at 1-23, at
http:l/www.cdc.gov/mmwr/preview/mmwrhtmOOO56669.htm.
91. "The majority of rotavirus infections are subclinical or cause mild gastrointestinal
illnesses that do not require hospitalization." Greenberg, Viral Gastronteritis, in HARRISON'S
PRINCIPLES OF INTERNAL MEDICINE, supra note 64, pt. 7 § 194, at 1117. This statement from
this well-respected medical treatise appears to be inconsistent with the claims of the CDC.
According to the CDC, rotavirus "accounts for more than 500,000 physician visits and ap-
proximately 50,000 hospitalizations each year among children aged less than 5 years." See
Centers for Disease Control, supra note 90.
92. There are 18,987,000 children five years of age and under living in the United States
according to U.S. Census Bureau Projections. See 1999 NEw YORK TiMES ALMANAC, 277
(John W. Wright ed. 1999).
93. See generally COMMirrEE ON INFECTIOUS DIsEASES, AMERICAN ACADEMY OF
PEDiATEJCs, 1994 RED BOOK: REPORT OF THE COMMITTEE ON INFECTIOUS DISEASES 225 (23r'
ed. 1994).
94. See American Academy of Pediatrics, supra note 41.
95. See Press release, National Vaccine Information Center, Hepatitis B Vaccine Reac-
tion Reports Outnumber Reported Disease Cases in Children According to Vaccine Safety
Group, Jan. 27, 1999 at http://www.909shot.conprhepb.htm; Michael Belkin, Testimony be-
fore the Advisory Committee on Immunization Practices-Centers for Disease Control and
Prevention, February 17, 1999 at http://www.909shot.comlacipmb.htm.
96. Hepatitis B Vaccine: Helping or Hurting Public Health Hearing Before Subcommit-
tee on Criminal Justice, Drug Policy, and Human Resources of the House of Representatives,
106 Cong. (May 18, 1999) [hereinafter Hepatitis hearings] (statement of Burton A. Wais-
bren, Sr. M.D.) at http:l/www.house.gov/reform/cjlhearings/99.05.18/waisbren.htm. "Infor-
mation regarding the risk/benefit ratio of this vaccine is not known and therefore cannot be
given to parents in an informed consent." Id.; Hepatitis hearings, supra (statement by Bonnie
S. Dunbar, Ph.D) at http://www.house.gov/reform/cjlhearings/99.05.18/dunbar.htm.
In view of this lack of scientific and medical information of neonatal immunology,
it is remarkable to me that newborn infants, especially those not at risk for the
Hepatitis B disease itself are being administered multiple injections of this vaccine
and that there have been few, if any, clinical trials to adequately evaluate the po-
tential long term effects of neonatal immunization especially as it relates to genetic
diversity.
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Category Number
Approximate number of deaths from 119,
Hepatitis B for children 1-14 (annualized)
Approximate number of deaths from 5398
Hepatitis B Vaccine for all ages (annual:
ized)
Approximate number of serious 19199
Injuries and/or Hospitalizations from
Hepatitis B for children 1-10 (annualized)
Approximate number of serious 828 0
Injuries and/or Hospitalizations from
Hepatitis B Vaccine for all ages
(annualized)
The figures are a result of an analysis of data from the Vaccine Adverse
Events Reporting System (VAERS), a federal database. They do suggest that
the hepatitis B vaccine may be more dangerous to children than hepatitis B.
In fact, the number of vaccine caused injuries and deaths may be even
higher. According to Dr. David Kessler, former director of the FDA, the
vaccine injury data from VAERS may only contain a "fraction" of all ad-
97. "In 1996, the number of deaths from viral hepatitis (of all types) reported in children
under the age of 14 was 11, and in children under the age of 1 year was 1." Vaccines: Public
Safety and Personal Choice, supra note 60 (statement by the Association of American Physi-
cians and Surgeons on Vaccines submitted by Dr. Jane Orient) at
http://www.aapsonline.org/aaps/testimony/hepbstatement.htm (citing tbl. 10, National Vital
Statistics Report 1998;47(9):51.).
98. This figure is based on an analysis of raw VAERS data conducted by Michael Bel-
kin, financial analyst at http://www.new-atlantean.conhepatiti.htm (last visited Nov. 23,
2000) (Mr. Belkin's data has been annualized and normalized to subtract deaths caused by
other vaccines). Injuries from the vaccine include: diabetes, partial blindness, lupus, polyneu-
ropathy, seizures, neurological damage, multiple sclerosis, vasculitis, cerebral aneurysm,
aseptic meningitis, cardiomyopathy, hepatitis, and other diagnosis requiring intubation. See
VAERS database at http://www.fedbuzz.comlvaccine/vac.html (last visited Nov. 23, 2000).
99. This figure is based on the following extrapolation: In the age group 0-10, there were
three reported cases of hepatitis B reported in New Hampshire from 1993 through 1997. This
is equal to .75 annual cases of hepatitis B for that state. In 1997, New Hampshire had ap-
proximately 148,000 children under the age of ten. The rate of hepatitis B in this age group
equals .75 per 148,000 or .000005. There are approximately 38,300,000 children under the
age of ten in the United States. The above rate equals 191 children in the U.S. stricken with
hepatitis B. For the number of reported cases of hepatitis B in New Hampshire see, Press re-
lease, Association of American Physicians and Surgeons, Physicians Oppose Mandatory
Hepatitis B Vaccine for New Hampshire School Children. Parents, Not Government Should
Decide, May 10, 1999, at http://www.aapsonline.org/aaps/press/nmhvac.htm. For the popula-
tion of New Hampshire see NEw YoRK TIMES ALMANAC, supra note 92, at 278.
100. See supra note 98.
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verse reactions.'0 ' This suggests that the deaths and injuries caused by this
vaccine and others are significantly underreported. Nonetheless, the Infec-
tious Diseases Society of America strongly objects to these findings citing
that "it is not possible to determine the number of adverse effects from a
given vaccine simply by looking at the number of VAERS reports."'" How-
ever, according to the medical treatise Vaccines, co-edited by Dr. Walter
Orenstein, Director of the CDC's National Immunization Program:
VAERS has successfully detected unrecognized potential reactions and
obtained data to evaluate whether these events are causally linked to vac-
cines... VAERS is also currently the only surveillance system that covers
the entire U.S. population with data available on a relatively timely basis.
It is, therefore, the major means available currently to detect possible new,
unusual, or extremely rare adverse events.'03
After undertaking their own analysis of the risks and benefits of the
hepatitis B vaccine for infants and children, the Association of American
Physicians and Surgeons"° called for an immediate moratorium on manda-
tory hepatitis B vaccines."5 Other physicians agree. Burton A. Waisbren, Sr.,
M.D. has stated, "the program of universal hepatitis B vaccination in the
United States is an experiment being performed on our babies. A morato-
rium should be placed on this experiment until risk/benefit ratios are clearly
defined.'"'"
In fact, after further study, the Association of American Physicians and
Surgeons called for a moratorium on all mandatory vaccination. 7 In a press
101. See Kessler, supra note 57. This former commissioner of the FDA has written, "Al-
though the FDA receives many adverse event reports, these probably represent only a fraction
of the serious adverse events encountered by providers." Id. Of course, it should be noted that
the number of injuries and deaths from hepatitis B itself may also be underreported.
102. Press release, Infectious Diseases Society of America, Recent Analysis of Hepatitis
B Data Misrepresents Risk of Vaccination, Jan. 22, 2000, at http://%vww.ama-assn.org/ama
/pub/article/1809-2052.html (American Medical Association website).
103. Chen, supra note 35, at 1151.
104.
The Association of American Physicians and Surgeons (AAPS) is a non-partisan
professional association of physicians in all types of practices and specialties
across the country... Since 1943, AAPS has been dedicated to the highest ethical
standards of the Oath of Hippocrates and to preserving the sanctity of the patient-
physician relationship and the practice of private medicine.
Association of American Physicians and Surgeons, at http://www.aapsonline.org/ (last visited
Feb. 1, 2001).
105. Press release, Association of American Physicians and Surgeons, Doctors Call for a
Moratorium on Hepatitis B Vaccine for Schoolchildren Citing Potential Deadly Outcomes,
(July 8, 1999) at http://www.aapsonline.org/aaps/press/hepbroe.htm.
106. Burton A. Waisbren, Sr., Universal Hepatitis B Vaccination: A Moratorium Should
Be Placed On This Experiment, at http:llwww.goodlight.netlnyvic/healthlhep-b/moratori.htm
(last visited Nov. 24, 2000).
107. At their 57th Annual Meeting, the Association of American Physicians and Sur-
geons (AAPS) unanimously passed a resolution calling for an end to mandatory childhood
[Vol. 37336
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release Jane M. Orient, M.D., the executive director of the organization
stated, "Our children face the possibility of death or serious long-term ad-
verse effects from mandated vaccines that aren't necessary or that have very
limited benefits."108
Concerned physicians and parents have suggested that the reason chil-
dren may be getting unneeded and potentially unsafe vaccines is due to the
major conflict of interest that exists at the level of vaccine policymaking.'"
These critics cite the millions of dollars in sales manufacturers enjoy when
their newest vaccine is approved for universal vaccination and they suggest a
financial motive behind the ever-expanding vaccination schedule."' They
also challenge the wisdom of permitting doctors who play key roles in de-
veloping new vaccines to sit on the federal advisory panels that make policy
decisions regarding their widespread use."' According to Dr. Orient, "It is
vaccines. See Press release, Association of American Physicians and Surgeons, Doctor's
Group Votes to Oppose Vaccine Mandates, Nov. 2, 2000 at http://www.aapsonline.org/
aapsfpresslnrvacres.htm.
108. Il
109. Compensating Vaccine Injuries: Are Reforms Needed? Before the Subcommittee on
Criminal Justice, Drug Policy, and Human Resources of the House of Representatives, 106'
Cong. (June 14, 1999)[hereinafter Vaccine Injury Hearings] (statement of Jane Orient, M.D.
Executive Director of the Association of American Physicians and Surgeons) ("Public policy
regarding vaccines is fundamentally flawed. It is permeated by conflicts of interest.") at
http://www.aapsonline.org/aaps/testimony/hepbcom.htm. See also Rock, supra note 22.
110. See ABC NEws, Vaccine Gets Federal Approval, (Feb. 17, 2000), at
http://www.abcnews.go.com/sections/living/DailyNews/vaccine000217.html. The newest
vaccine approved for universal vaccination is a pneumococcal conjugate vaccine called Prev-
nar. Id. Four doses of Prevnar (the amount for each child starting at two months old) sells for
$232. ld. According to pharmaceutical industry-financial analysts interviewed by the news
agency Reuters, Prevnar is expected to deliver sales of $300 to $500 million a year for its
manufacturer Wyeth-Lederle Vaccines. Id.
In addition, once a vaccine is added to the CDC's childhood vaccination schedule, manufac-
turers will sell millions of units because most children are required to have the vaccine to en-
ter school. See Vaccine Controversies, 10, No. 28, CQ RESEARCHER, 645 (2000). This also
makes it much more likely that the vaccine will be recommended by the World Health Or-
ganization for distribution in third world countries, guaranteeing millions of additional units
to be sold. Id. Furthermore, the rising prices of vaccines contributes to this multi-billion dollar
industry. Id. "A key feature of Pasteur Merieux Connaught projections for a $20 billion vac-
cine market by 2007 is the continuously rising prices of new vaccines." See PMC/Oravax to
Begin Phase I Studies for H. Pylori Vaccine in 1999, 60 (No. 48) PINK SHEET 14 (1998).
111. See Hepatitis Hearings, supra note 96 (statement by Bonnie S. Dunbar, Ph.D.) at
http:llwww.house.gov/reformlcj/hearings/99.05.18/dunbar.htm. "It is well documented, how-
ever, that committee members advising the CDC and members of organizations (such as the
American Academy of Pediatrics, and the World Health Organization) obtain substantial
funding from pharmaceutical companies. Furthermore it is well documented that investigators
who have carried out clinical trials on this vaccine also benefit personally and obtain labora-
tory funding as consultants promoting the vaccine and as expert witnesses in legal conflicts. I
leave it up to this distinguished committee to investigate and evaluate the seriousness of these
apparent conflicts of interest" ld. See also Harold Buttram, M.D., Vaccine Scene 1999: Over-
view And Update at http://www.whale.to/vaccines/buttraml.html (last visited February 17,
2001).
Today we have a system in which vaccine production by the pharmaceutical
companies is largely self-regulated. Of course these companies are interested in
17
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apparent that critical medical decisions for an entire generation of American
children are being made by small committees whose members have incestu-
ous ties with agencies that stand to gain power, or manufacturers that stand
to gain enormous profits, from the policy that is made.""'
H1. CONFLICTS OF INTEREST IN VACCINE TESTING AND POLICYMAKING
. A. Congressional Investigation
To determine if a conflict of interest exists in federal vaccine policy-
making, the House of Representatives Committee on Government Reform
began an investigation in August 1999."' Congressional hearings were held
on June 14, 2000 and a committee report was published on August 21,
2000.2" This report focused on two influential committees: the FDA's Vac-
cines and Related Biological Products Advisory Committee (VRBPAC) and
the CDC's Advisory Committee on Immunization Practices (ACIP)." Both
committees help determine U.S. vaccine policy."' The investigation exam-
ined the activities of these committees in reference to the approval of a vac-
cine called RotaShield."7
Manufactured by Wyeth-Lederie, RotaShield was designed to protect
children against a virus that causes diarrhea."' It was approved by the FDA
on August 31, 1998."' Distribution began on October 1, 1998.2" By May
1999, life-threatening intussusception"' injuries were reported. "' The num-
ber of injuries continued to increase and there was at least one death."
panies is largely self-regulated. Of course these companies are interested in profits
from their products which, in itself, is not wrong. However, when arbitrary deci-
sions in the mandating of vaccines are made by the government bureaucracies,
which are highly partisan to the pharmaceuticals, with no recourse open to parents,
we have all the potential ingredients for a tragedy of historical proportions.
112 Vaccine Injury Hearings, supra note 109 (statement of Jane Orient).
113. MAJORrY STAFF REPORT, supra note 29, at 1.
114. See generally Conflicts of Interest and Vaccine Development, supra note 23;
MAJORITY STAFF REPORT, supra note 29.
115. MAJORITY STAFF REPORT, supra note 29, at 1-2.
116. Id. at 1. "The VRBPAC advises the FDA on the licensing of new vaccines, while
the ACIP advises the CDC on guidelines to be issued to doctors and the states for the appro-
priate use of vaccines." Id.
117. Id. at2.
118. Centers for Disease Control, supra note 90.
119. MAJORrrY STAFF REPORT, supra note 29, at 2, 8.
120. aIk at 8.
121. For a definition of intussusception, see supra note 30.
122. MAJoRrY STAFF REPORT, supra note 29, at 10. "May 1999 there were ten cases of
intussusception reported in the VAERS System." Id.
123. Id. (citing minutes of ACIP meeting, October 22, 1999, 56-57 - "As of October 15,
1999, 113 cases of intussuseption had been received. Nine of these reported cases were de-
termined not to be intussuseption. Of the remaining 102 cases... 57 had received the vac-
cine... 29 required surgery, seven underwent bowel resection, and one five-month-old infant
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Wyeth-Lederle suspended further distribution and administration of the vac-
cine on July 16, 1999, and withdrew it from the market on October 15,
1999.1'4
According to a congressional investigation, the vaccine's clinical trials
prior to approval demonstrated an intussusception rate of 5 in 10,054 chil-
dren." These figures are significant. Based on injecting 3,800,000 chil-
dren'26, the anticipated number of injuries was approximately 1,865 per
year.2 7 Such a large number of injuries and potential deaths eclipse whatever
benefit the vaccine might provide in preventing diarrhea.' The pre-market
studies also demonstrated concerns about children "failing to thrive," devel-
oping high fevers which can lead to brain injury, and experiencing growth
retardation.'29 Although the advisory committees were aware of this informa-
tion, they voted unanimously to approve the vaccine.'
1. Food and Drug Administration's Vaccines and Related Biological
Products Advisory Committee (VRBPAC)
The Committee on Government Reform investigated who the partici-
pants were on the FDA's vaccine advisory committee (VRBPAC). The in-
vestigation revealed that the same participants sat on the committee for
many years despite term limits,' four of the five permanent members who
voted for RotaShield had conflicts of interest that necessitated waivers, and
died after developing intussuseption five days after receipt of the vaccine.").
124. Press release, American Home Products Corporation, Wyeth Lederle Vaccines Vol-
untarily Withdraws from the Market its Rotavirus Vaccine Rotashield (Oct. 15, 1999) (on file
with author).
125. MAJOrrY STAFF REPORT, supra note 29, at 11 (citing RotaShield Package Insert,
Wyeth-Ayerst, 13).
126. There are 18,987,000 children five years of age and under living in the United
States according to U.S. Census Bureau Projections. Children under one year of age constitute
20% or approximately 3,800,000 individuals. See NEW YORK TiMEs ALMANAC, supra note 92
at 277. RotaShield was targeted to children in this age group. See Centers for Disease Control,
supra note 90.
127. According to the Congressional investigation, five children out of 10,054 suffered
from intussusception during the pre-market study of RotaShield. MAJORITY STAFF REPORT,
supra note 29, at 11. This rate is equivalent to 1,865 children out of 3,800,000, the size of the
target population for this vaccine.
128. The vaccine had a predicted efficacy of 49% to 83%. See id. at 7-8. Number of
deaths from Rotavirus was approximately 20 per year. See supra note 90.
129. MAJORITY STAFF REPORT, supra note 29 at 15. See also Wyeth RotaShield Viral
Transmission Risk to Immunocompromised Family Members Should be in Labeling, 59 (No.
51) THE PINK SHEET 13 (1997). "Wyeth provided committee members with information that
mentioned seven hospitalizations for febrile illness in RotaShield patients and two on pla-
cebo. . ." Id. Growth retardation was diagnosed in .7% of patients receiving RotaShield and
failure to thrive in .5%. Id.
130. MAJORITY STAFF REPORT, supra note 29, at 15-17.
131. Id. at20.
132. Id. at 16.
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other conflicts of interest were permitted without even requiring a waiver.'
The conflicts were varied. Committee members owned stock in vaccine
companies, were involved in RotaShield development, had participated in
licensing the vaccine to RotaShield's manufacturer, and had received tens or
hundreds of thousands of dollars in grants from Wyeth-Lederle."M The con-
gressional investigation concluded, "The overwhelming majority of mem-
bers, both voting members and consultants, have substantial ties to the
pharmaceutical industry."'35 Dr. Thomas Fleming, Chair of Biostatistics at
the University of Washington, was a temporary voting member at the meet-
ing. Speaking about the known side effects of the vaccine he stated:
[Therefore] I would ask the FDA to work with the sponsor to further quan-
titate what these serious side effects are-specifically the adverse effects,
driven in particular by febrile illness-is inducing hospitalizations and
what is that level of excess. I still don't feel like I have a good grasp of
that at this point.'36
133. Id. at 16-17.
134. Id. at 17-19. The report found that:
([Dr. Patricia Ferried chaired the discussion on the approval of RotaShield.] At the
time of the proceedings, Dr. Ferrieri owned about $20,000 of stock in Merck, an
affected company and manufacturer of an upcoming rotavirus vaccine. [Dr. Caro-
line Hall's employer] the University of Rochester, had a $9,586,000 contract with
the National Institute for Allergy and Infectious Diseases (NIAID), the original
developer of the rotavirus vaccine. [NIAID subsequently licensed RotaShield to
Wyeth-Lederle.] [Dr. Kathryn Edwards] received a contract from Wyeth-Lederle
for $255,023 per year from 1996 to 1998 for the study of pneumococcal vaccines.
She also had numerous grants and contracts with the NIAID, [the original devel-
oper of RotaShield], for research on other vaccines. [Dr. Mary Estes] employer,
Baylor College of Medicine, was receiving a large amount of funds for the devel-
opment of rotavirus vaccines, including a $75,000 grant from American Home
Products, the parent company of Wyeth-Lederle Vaccines, and a $404,000 grant
from National Institute for Allergy and Infectious Diseases from 8/93 to 7/98....
Dr. Estes was also listed as the principal investigator for a grant from Merck for
the development of a rotavirus vaccine. [Ms. Rebecca Cole is] an advocate for
vaccines and has received both travel expenses and honoraria from Merck. [Merck
is also producing a Rotavirus vaccine.] [Dr. Neal Halsey, a consultant, has re-
ceived] numerous grants from various vaccine manufacturers. [He has also re-
ceived] frequent reimbursements for travel expenses and honoraria from...
Merck .... He has already received $50,000 from Merck and was awaiting funds
from Wyeth Lederle. Dr. Halsey also participated in the rotavirus working group of
the ACIP.[Furthermore], Dr. Halsey was the Chair of the Committee on Infectious
Diseases and representative of the American Academy of Pediatrics which, in con-junction with the CDC, sets and advertises the recommendations for schedules and
dosages of immunizations. [Dr. John Modlin] owned approximately $26,000 of
stock in Merck, an affected company [and] has served on Merck's Immunization
Advisory Board from 1996 to the present. [In addition] Dr. Modlin was at the time
the Chairman of the ACIP and its rotavirus working group.
Id.
135. Id. at 19.
136. Id. at 16.
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Even with these serious concerns Fleming voted to approve the vaccina-
tion for immediate use as did all the other members.
37
2. The Centers for Disease Control and Prevention Advisory Committee on
Immunization Practices (ACIP)
The CDC's Advisory Committee on Immunization Practices (ACIP)
held eight separate votes regarding RotaShield between February 11, 1998,
and June 17, 199938 The Congressional Investigation revealed that the
ACIP, "recommended the RotaShield for universal use before it was even
approved by the FDA.'' 39 The investigation also found that: every member
was granted a blanket waiver regardless of conflicts of interest for up to a
year; ACIP members vote on vaccine recommendations even when they
have financial ties to drug companies developing related vaccines; some
ACIP members sit on both the FDA and ACIP advisory committees contrary
to the rules; and ACIP members do not fully disclose their conflicts of inter-
est.""'
Some of the financial ties between these CDC advisory members and
the vaccine manufacturers were just as dramatic as those found for the FDA
committee members. These conflicts included: actually owning the patent on
a similar rotavirus vaccine, receiving consulting fees and grants from the
manufacturer, and owning thousands of dollars of stock in various vaccine
'41companies. *
The Congressional Investigation also revealed that the actual recom-
mendation was written by the ACIP "rotavirus working group." According
to the investigation, "The working group has ten members, seven of whom
have identifiable conflicts of interest with vaccine manufacturers or vaccine
interest groups. The group's meetings were held in private with no minutes
or records of the proceedings taken."'42
The investigation also detailed the conflicts of interest of the liaison rep-
137. Il
138. Id. at 28.
139. Id. at 36.
140. Id at 26-27.
141. Id. at 28-30 (In respect to financial ties to drug companies, the congressional report
highlighted these ACIP members: Dr. John Modlin serves on Merck's Advisory Board, owns
stock in the company and was chairman of the Rotavirus working group; Dr. Paul Offit shares
the patent on the rotavirus vaccine being developed by Merck and voted yes three times to
recommend RotaShield but abstained from voting to rescind the vaccine when RotaShield
related injuries were reported; Dr. Fernando Guerra has contracts with most of the large vac-
cine producers including Merck, Pasteur Merieux Connaught, and Medimmune; Dr. Marie
Griffin received consulting fees and expenses from Merck and her husband has consulted for
American Cyanamid the parent company of Wyeth-Lederle; Dr. T. Chinh Le's employer Kai-
ser Permanente participates in vaccine studies with Wyeth-Lederle, Merck and SmithKline-
Beecham; Dr. Richard Clover received educational grants from Merck and SmithKline-
Beecham.).
142. Id. at 32.
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resentatives who vote in the working groups and draft vaccine recommenda-
tions. According to the Congressional Report, liaison representatives are not
required to disclose financial conflict of interest and the report noted that of
the seven ACIP liaison representatives all seven "have ties to numerous vac-
cine manufacturers."'43 One liaison represented the Pharmaceutical Research
and Manufacturers of America which is a trade group consisting of 100 vac-
cine and drug manufacturers.'"
The Congressional Report concluded that in respect to the ACIP, the
"automatic [conflict of interest] waivers given to every advisory committee
member," the use of working groups in which conflict of interest procedures
are not even used, and the "absence of consumer representation" allows spe-
cial interest groups with vested interests to unduly influence the govern-
ment.' 5
B. The Newest Vaccine for Children-Prevnar
Injuries related to Wyeth-Lederle's vaccine RotaShield were reported in
May 1999.'" Two months prior, in March 1999, the FDA granted a "priority
review" to another "novel" Wyeth-Lederle vaccine called Prevnar."7 Prevnar
is marketed to prevent pneumococcal infections that can cause earaches,
meningitis, bacteremia and pneumonia.'" Every year, approximately 42 chil-
dren under the age of two years die of pneumococcal meningitis in the
U.S.49 People who are more likely to get pneumococcal infections usually
have predisposing conditions such as immunoglobulin deficiency, Hodgkin's
disease, congenital or acquired immunodeficiency (including HIV),
nephrotic syndrome, some viral upper respiratory tract infections, splenic
dysfunction, splenectomy and organ transplantation.'" Despite these known
143. Id at 31.
144. I. at 32. For the member vaccine and drug companies that are part of the Pharma-
ceutical Research and Manufacturers of America see http://www.phrma.org/publications/
publications/annual2000/members.phtml (last visited on Oct. 29, 2000).
145. MAJORITY STAFF REPORT, supra note 29, at 34-35.
146. 1l at 10.
147. "In March 1999, Prevnar, a novel, seven-valent pneumococcal conjugate vaccine,
was granted a 'priority review' by the FDA." AMERICAN HOME PRODUCTS CORPORATION,
1999 ANNUAL REPORT 4 (2000).
148. Package Insert, supra note 82.
149. Id. The manufacturer states that "The annual incidence of pneumococcal meningitis
in children between I to 23 months of age is approximately 7 cases per 100,000 persons" and
that this disease "has been associated with 8% mortality." Id. Seven cases per 100,000 =
.00007%. Eight percent mortality = .0000056. .0000056 of 7,500,000 (the approximate num-
ber of children under two-years of age) = 42 children. For the approximate number of children
in the U.S. under two years of age see NEw YORK TIMES ALMANAC, supra note 92, at 277. See
also Centers for Disease Control, CDC's Pneumococcal Conjugate Vaccine: What You Need
to Know, at http://www.cdc.gov/nip/ publications/VIS/vis-pneumoConjugatelnterim.pdf (last
visited on Mar. 7, 2001) According to the CDC, pneumococcal disease is responsible for
about 200 deaths each year in children under five years of age. Id
150. COMMITTEE ON INFECTIoUs DISEASES AMERICAN ACADEMY OF PEDIATRICS, supra
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risk factors and the fact that 20 to 40 percent of healthy children have been
found to already carry this micro-organism, 5' the American Academy of Pe-
diatrics Committee on Infectious Diseases has recommended universal vac-
cination for all children.' Every child in America should receive four doses
of the vaccine at 2, 4, 6, and 12-15 months of age.5 1
The primary tests to determine the vaccine's safety and efficacy were
undertaken by Drs. Black and Shinefield of Kaiser Permanente.' These
studies were paid for by Wyeth-Lederle, the vaccine's manufacturer.55 In
fact, these doctors appear in a glossy photo in American Home Products'
1997 Annual Report. 5 ' The conferences these doctors attended to introduce
note 93, at 371; COMMrITEE ON INFECTIOUS DISEASES AMERICAN ACADEMY OF PEDIATRICS,
1997 RED BOOK: REPORT OF THE COMMITTEE ON INFECTIOUS DISEASES 411 (1997).
151. Daniel M. Musher, Pneumococcal Infections, in HARRISON'S PRINCIPLES OF
INT3RNAL MEDICINE, supra note 64, pt. 7 § 5, at 870 ("S. pneumoniae colonizes the nasophar-
ynx and can be isolated from 5 to 10 percent of healthy adults and from 20 to 40 percent of
healthy children").
152. American Academy of Pediatrics, Policy Statement: Recommendations for the Pre-
vention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine
(Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis (RE9960) 106
PEDIATRICS 362-366 (2000), at http:llwww.aap.org/policy/re9960.html
153. Id. In addition to mortality, the morbidity associated with any disease must always
be considered in any cost-benefit analysis of vaccination. In respect to bacteremia, a leading
medical treatise states, "Almost all children with occult pneumococcal bacteremia recover
uneventfully if they are treated with parenteral antibiotics when first seen.. ." David S. Fed-
son, et al., Pneumococcal Vaccine, in VACCINES, supra note 26, at 568. In respect to pneumo-
nia, the same treatise states, "[iun children 6 months of age and younger who live in developed
countries, pneumococcal infection rarely causes serious lower respiratory tract disease requir-
ing hospitalization." Id. at 567. Morbidity associated with meningitis can be severe and in-
clude mental retardation, deafness or seizure disorder. Id. at 568. However, it appears that
there are only 525 cases per year in children under 23 months of age in the U.S. Musher, su-
pra, note 151. Arguably many of these cases may be associated with the risk factors outlined
by the American Academy of Pediatrics. See American Academy of Pediatrics, supra note
152.
154. See, e.g., Henry Shinefield & Steven Black, Efficacy of Pneumococcal Conjugate
Vaccines in Large Scale Field Trials, 4 PEDIATR. INFECT. DISEASES J. 394-97 (2000); StevenBlack et al., Eficacy, Safety and Immunogenicity of Heptavalent Pneumococcal Conjugate
Vaccine in Children. Northern California Kaiser Permanente Vaccine Study Center Group, 3
PEDIATR. INFECT. DISEASES J. 187-95 (2000); T. A. Lieu et al., Projected Cost-Effectiveness of
Pneumococcal Conjugate Vaccination of Healthy Infants and Young Children, 11 JAMA
1460-8 (2000); and Henry Shinefield et al., Safety and Immunogenicity of Heptavalent Pneu-
mococcal CRM197 Conjugate Vaccine in Infants and Toddlers, 9 PEDIATR. INFECT. DISEASES
J. 757-63 (1999).
155. Press Release, Harvard Medical School Office of Public Affairs, Researchers Find
Use of Pneumococcal Conjugate Vaccine for Children Could Reduce Disease-Related Costs,
March 14, 2000 at http://www.hms.harvard.edu/news/releases/0300]ieu.html ("study was
supported by a grant from Wyeth Lederle Vaccines & Pediatrics"). Associated Press, New
Vaccine Reduces Risk of Severe Pneumonia in Children, (Oct. 1, 1999), available at
http://www.idahonews.com/10011999/health_a/386.htm ("Wyeth-Lederle Laboratories "paid
for the testing").
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the vaccine to other clinicians were also paid for by the manufacturer.'"
Another doctor who accompanied Drs. Black and Shinefield to a con-
ference was Dr. Kathyrn Edwards.' Wyeth-Lederle paid Dr. Edwards
$255,023 per year from 1996 to 1998 for the study of pneumococcal vac-
cines (i.e. Prevnar).59 Edwards is also one of fifteen full-time members of
FDA's vaccine advisory committee (VRBPAC) that recommended that the
vaccine be approved." In addition, she answers questions regarding Prevnar
on a pro-Prevnar website called "pneumo.com" which is paid for by Wyeth-
Lederle. 6 1
Some of Dr. Edwards' answers to questions appear to be misleading. A
mother named Susan wrote to Dr. Edwards on September 6, 2000 and said:
"(I read) some disturbing comments from parents whose children have al-
ready received the vaccine. They said it has terrible side effects, such as poor
appetite, difficulty breathing, sleeping problems, and can cause juvenile dia-
betes.. .of course this has me worried."'' Dr. Kathryn Edwards responded
on September 12, 2000, "The vaccine was administered to nearly 20,000
children prior to licensure and the side effects seen in these children were
carefully evaluated and not shown to increase the rate of diabetes, respira-
tory problems, or weight loss."' " Contrary to Dr. Edwards' comments, one
doctor has stated publicly that he is concerned that Prevnar may cause diabe-
tes." In addition, during the pre-market studies, cases of croup, pneumonia,
asthma, bronchiolitis, and wheezing were diagnosed within three days of
administration of Prevnar.'6
157. See MEDREGISTER, Preventing Pediatric Diseases-A Continuing Medical Educa-
tion Course, at http://www.mededregister.com/vaccine.html (last visited May 26, 2000) (Con-
ference to present Prevnar in Washington D.C. on October 8, 1999 was "supported by an un-
restricted educational grant from Wyeth Lederle vaccines"); 9h International Congress on
Infectious Diseases, April 10-13, 2000, Buenos Aires, Argentina, at http://isid.organize-
it.com/9th-congress/saLsymposia.html (last visited May 26, 2000) (Conference was "spon-
sored by Wyeth Lederle vaccines"); Pediatric Academic Societies & American Academy of
Pediatrics Joint Meeting - Haynes Convention Ctr. May 16, 2000, at http://www.aps-
spr.org/Meetings/2000/Monday.htm (last visited May 27, 2000) (Conference was "supported
in part by an educational grant from Wyeth-Lederle Vaccine and Merck Vaccine Division").
158. See http:llwww.aps-spr.orglMeetingsl200O/Monday.htm.
159. MAJORITY STAFF REPORT, supra note 29, at 17.
160. id.
161. Pneumo.com, Ask an Expert, at http://pneumo.com/contact/contact2.htm (last vis-
ited on Sep 14, 2000) (The site is "supported by an unrestricted educational grant from
Wyeth-Lederle Vaccines").
162. Pneumo.com, Online Forum at http://www.pneumo.conmsgboard/messagcs
/parent-messages.html (last visited Sept. 13, 2000) (on file with author).
163. Id.
164. Dr. J. Bart Classen told the FDA that Prevnar "may be seven times as toxic as the
hemophilus vaccine, possibly causing an estimated 400 to 700 children to develop insulin de-
pendent diabetes per 100,000 children immunized. These cases of diabetes may not occur un-
til 3.5 to 10 years following immunization." Press release, Classen Immunotherapies, New
'Tuskegee-Like Experiment' Planned with Pneumococcal Pneumonia Vaccine, Reported by
Classen Immunotherapies (Feb. 18, 2000), at http://vaccines.net/pneumoco.htm.
165. Package Insert, supra note 82.
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Another doctor, Margaret Rennels, was involved in RotaShield and has
participated in testing the safety of Prevnar.'" The major vaccine and drug
manufacturers (including Wyeth-Lederle) have donated a total of over $2.5
million to the University of Maryland School of Medicine where Dr. Ren-
nels works. 7 In addition, she is one of the twelve members of the Commit-
tee on Infectious Diseases, the committee that makes vaccine recommenda-
tions as part of the American Academy of Pediatrics.'68
Although it is FDA approved, it appears that Prevnar has not undergone
thorough testing for either safety or efficacy. The manufacturer acknowl-
edges that, "Prevnar has not been evaluated for any carcinogenic or muta-
genic potential, or impairment of fertility."'69 The manufacturer also states
that when Prevnar is administered simultaneously with other vaccines it may
interfere with the effectiveness of at least two other vaccines.' ° Additional
studies with Prevnar given in conjunction with other childhood vaccines
used very small numbers of children of between 0-214.'"' Finally the efficacy
of Prevnar in respect to ear infections is only 7%72 and it reportedly reduces
166. Margaret Rennels et al., Safety and Immunogenicity of Heptavalent Pneumococcal
Vaccine Conjugated to CRM197 in United States Infants, 101 PEDIATRIcs 604-11 (1998).
167. University of Maryland School of Medicine Donors, and Medical System Donors,
at http:llwww.umm.edulannualreport/9798ar/sitelmain.htm (last visited Sept. 14, 2000).
(Examples include: Warner-Lambert Company - 1,000,000-4,999,999; Parke-Davis -
$500,000-$999,999; Hoffman LaRouche, Inc. - $250,000-$499,999; Merck & Company -
$250,000-$499,999; Bristol-Myers Squibb - $250,000-$499,999; SmithKline-Beecham
$100,00-$249,999; Abbott Laboratories - $10,000-$49,999; Pfizer Inc. - $10,000-$49,999;
Wyeth-Ayerst Laboratories $10,000-$49,999 to Medical System and $10,000-$49,999 to
Medical School; American Cyanamid - $1,000-$9,999).
168. See Gary D. Overturf & Committee on Infectious Diseases, Technical Report: Pre-
vention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate and Poly-
saccharide Vaccines and Antibiotic Prophylaxis (RE9960), 106 PEDIATRICS 367-76 (2000), at
http://www.aap.org/ policy/re9960t.html.
169. Package Insert, supra note 82.
170. Id. Under "Simultaneous Administration with Other Vaccines," the package insert
states:
Although some inconsistent differences in response to pertussis antigens were ob-
served, the clinical relevance is unknown. The response to 2 doses of IPV given
concomitantly with Prevnar assessed 3 months after the second dose, was equiva-
lent to controls for poliovirus Types 2 and 3, but lower for Type 1. MMR and
Varicella immunogenicity data from controlled clinical trials with concurrent ad-
ministration of Prevnar are not available.
Id.
171. Id. According to the Wyeth-Lederle, for the study concerning DPT and Hib efficacy
with Prevnar, the number of infants reviewed (who were given Prevnar) was a total of 214. Id.
For toddlers the total number was forty-seven children. Id. For reviewing the efficacy of Hep
B with Prevnar the number of infants studied (who were given Prevnar) was 156. Id. For tod-
diers the total number was zero. Id. The numbers of children tested (214, 47, 156, and 0) do
not appear to be statistically valid in comparison to the over seven million infants and toddlers
are scheduled to receive this vaccine.
172. Press Release, Kaiser Permanente, Investigational Vaccine is First to Show Effec-
tiveness Against Childhood Ear Infections, (May 4, 1999), at http://www.kaiserpermanente.
org/newsroom/releases/vaccinel.html. "In the primary analysis of all acute otitis media epi-
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reduces the chances of a child under two years of age of getting pneumococ-
cal disease from 0.15% (without Prevnar) to 0.02% (with Prevnar). '
Even with the conflicts of interest, incomplete testing, questionable ne-
cessity, and lackluster efficacy, this vaccine was given a priority review by
the FDA and approved for universal vaccination." Injuries and reactions
have already been reported. 75
Ill. PROTECTING CHILDREN THROUGH REESTABLISHING INTEGRITY IN
VACCINE POLICYMAKING AND ALTERNATIVE LEGAL STRATEGIES
A. Parameters for Solutions
In order to protect children from potentially unsafe or unnecessary vac-
cines two parameters must be applied to any potential solution. The first pa-
rameter considers how well the approach provides for neutral, fair, and sci-
entifically sound analysis regarding the vaccine's necessity, safety and
efficacy. The second adjudges how well it provides parents with information
and the opportunity to exercise informed consent. Any solution that fulfills
both parameters will serve to protect children and optimize their health.
B. An Attempt to Eliminate Conflicts of Interest
The various rules concerning federal advisory committees allows the
FDA and CDC to issue waivers and permits doctors with conflicts of interest
to participate in their respective vaccine committees."" Without these waiv-
sodes [i.e. earaches] ... children receiving the investigational 7-valent pnemococcal vaccine
[i.e. Prevnar] had 7 percent fewer new episodes." Id.
173. Package Insert, supra note 82. Data derived from the text and figures in Table I of
the package insert. Based on the intent to treat figures (children who received at least one
dose of the vaccine), if you do not vaccinate with Prevnar the risk is approximately 20 in
100,000 (0.020%) for all persons, and 150 in 100,000 (0.15%) for children under two. If you
do vaccinate with Prevnar, the risk decreases to 3 out of 18,906 (.016) rounded to .02%.
174. See AMmiCAN HoME PRODUCTS, supra note 147.
175. See generally Pneumo.com Online Forum, at http://www.pneumo.com/msgboard/
messages/parent-messages.html (last visited Sept. 13, 2000). This bulletin board contains an-
ecdotal information - questions from parents whose children have been administered Prevnar
and who have had adverse reactions such as: pneumonia, vomiting, rashes, inflammation, fe-
vers, etc. Id. See also News 8 Investigates: Prevnar-Part I (WFAA television broadcast (Dal-
las) Feb. 22, 2001) ("[A]s part of our investigation, News 8 reviewed nearly 800 adverse reac-
tion reports filed with the FDA during past nine months. What we found is that one of out 10
children who had suspected side effects suffered some sort of seizure").
176. There are three groups of rules that regulate federal advisory committees. The first
is the Federal Advisory Committee Act (FACA). 5 U.S.C.A. app. 2 § 1 et seq. (West,
WESTLAW through P.L. 106-274, approved Sept. 22, 2000). FACA was enacted in 1972. Id.
Its purpose is to better control spending on advisory committees and make the committees
more accountable to the government. See id. To accomplish this, FACA provides recommen-
dations on the scope of the committees, requires the meetings to be open to the public, and
requires that committees contain balanced membership that is not "inappropriately influenced
by special interests." 5 U.S.C.A. § 5. The second area of law that controls the advisory
committees is 18 U.S.C. §§ 202-209 that address conflicts of interest. 18 U.S.C.A. §§ 202-209
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ers, these physicians could be subject to fines or imprisonment.'77 Both agen-
mittees is 18 U.S.C. §§ 202-209 that address conflicts of interest. 18 U.S.C.A. §§ 202-209
(West, WESTLAW through P.L. 106-274, approved Sept. 22, 2000). This statute defines ad-
visory committee members as Special Government Employees (SGE's). 18 U.S.C.A. § 202.
The statute generally prohibits SGE's from participating in decision making when they have a
conflict of interest. However, there are three waivers available: (b)(1) waivers are used when
the appointing official decides the individuals conflict of interest is too insubstantial to effect
the integrity of the policymaking; (b)(2) waivers are extended when the conflict of interest is
too remote to have any effect at all; (b)(3) waivers are used when the appointing official de-
termines that "the need for the employee's services outweigh the potential conflict of interest
by the employee's financial interest." 18 U.S.C.A. § 208. The last group of rules that directly
impacts federal advisory committees is the Code of Federal Regulations and Office of Gov-
ernment Ethics. 5 C.F.R. 2640 (West, WESTLAW through P.L. 106-274, approved Sept. 22,
2000). These rules interpret 18 U.S.C. §§ 201-219 and provide more specific regulations
regarding what types of conflict of interest can exclude SGE's (absent a waiver). Id. The three
waivers 18 U.S.C. §§ 208 (b)(1-3) and the construction of the various rules give the appoint-
ing officials in each agency tremendous latitude in appointing committee members and waiv-
ing or discounting conflicts of interest. Id. In fact, the FDA and CDC rely on the (b)(3) waiv-
ers to justify their allowing of committee members with significant conflicts of interest to
participate in the meetings. See Conflicts of Interest and Vaccine Development, supra note 23
(June 15, 2000) (statement by Linda Suydam, D.P.A. Senior Associate Commissioner, FDA),
at http://www.house.gov/reformlhearings/healthcaret0.06.15/ suydam.htm.
Under section 18 U.S.C. 208(b)(3), an SGE, who may be a standing or temporary
member, may participate in an advisory committee meeting despite a potential
conflict of interest. After reviewing the SGE's financial disclosure statements, the
Senior Associate Commissioner may determine that the need for the employee's
services outweighs the potential conflict of interest created by the financial interest
involved.
Id. "Congress has recognized the need for service on federal advisory committees by these
experts and has provided for waivers of the conflict of interest prohibitions under 18 U.S.C. §
208 when the need for the individual's services outweighs the potential for a conflict of inter-
est created by the financial interest involved." Id. (statement by Dixie Snider).
For a discussion of FACA see Kurtis A. Kemper, J.D., Annotation, Construction and Applica-
tion of Federal Advisory Committee Act (5 U.S.C.A. app. 2 §§ 1-15), 160 A.L.R. FED. 483
(2000). For a discussion of 18 U.S.C. §§ 202-209 see Lewis J. Heisman, J.D., Annotation,
What Constitutes Acts Affecting Personal Financial Interest Within Meaning of 18 U.S.C.A. §
208(a), Penalizing Participation by Government Employees in Matters in Which They Have
Personal Financial Interest, 59 A.L.R. FED. 872 (1982). For a discussion of Code of Federal
Regulations and Office of Government Ethics (5 C.F.R. 2640) see FACA: Conflicts of Interest
and Vaccine Development: Preserving the Integrity of the Process, Before the Government
Reform Committee of the House of Representatives, 106' Cong. (June 15, 2000) (statement
of Marilyn L. Glynn, General Counsel, Office of Government Ethics). For an overview of all
three rules in terms of federal vaccine advisory committees see MAJORrrY STAFF REPORT, su-
pra note 29, at 3-6.
177. 18 U.S.C. § 216(b):
The Attorney General may bring a civil action in the appropriate United States dis-
trict court against any person who engages in conduct constituting an offense un-
der section 203, 204, 205, 207, 208, or 209 of this title and, upon proof of such
conduct by a preponderance of the evidence, such person shall be subject to a civil
penalty of not more than $50,000 for each violation or the amount of compensation
which the person received or offered for the prohibited conduct, whichever amount
is greater. The imposition of a civil penalty under this subsection does not preclude
any other criminal or civil statutory, common law, or administrative remedy,
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cies argue that they are liberal with waivers because they claim that they can
not find vaccine experts without conflicts.' This reason appears dubious.
Recently, when the Institute of Medicine formed a committee to examine the
relationship between vaccines and autism they found expert doctors with
fewer direct conflicts.'79 Some scientists see the FDA's and CDC's explana-
tion as little more than an excuse. Dr. Gordon Stewart has studied the pertus-
sis vaccine for decades and has stated, "[There's] something like one hun-
dred people [who] are pretty well controlling what goes on in the entire
world of vaccines. They are all in cahoots with each other and with the
pharmaceutical companies.' ' 0
The section that permits these liberalized waivers, 18 U.S.C. § 208
(b)(3), was enacted in 1989."' Although the Supreme Court has not had an
which is available by law to the United States or any other person.
178. Conflicts of Interest and Vaccine Development (statement of Linda Suydam), supra
note 176
(United States is increasingly supported by industry. For that reason, outside ex-
perts and research centers where they work, frequently have research grants from
and contracts with regulated industry. Thus most active researchers in the private
sector have some ongoing or past relationship with regulated industry. This, by it-
self, does not preclude them from serving as Special Government Employees. If
this were the case, FDA would not get the top scientists in the field and recom-
mendations of the advisory committees would not be of the highest scientific na-
ture, with a likely impact on public health)
MAJORITY STAFF REPORT, supra note 29, at 3-6; Conflicts of Interest and Vaccine Develop-
ment (statement of Dixie Snider), supra note 23.
(Federal advisory panels inherently have members who may have potential finan-
cial conflicts of interest because... the members are chosen for service based on
their expertise in the areas in which advice is sought by the government. Experts in
the vaccine field frequently have affiliations with, or may be engaged in research
conducted by academic institutions or other institutions which may receive funding
from vaccine manufacturers.).
During the hearing, Congress was told that it was theoretically possible for the CEO of a vac-
cine manufacturer to be invited to participate on a federal vaccine advisory panel. Conflicts of
Interest and Vaccine Development, supra note 23, at transcript lines 1188-1192 (conversation
between Congressman Dan Burton and Marilyn L. Glynn , General Counsel, Office of Gov-
ernment Ethics).
179. Representative Dan Burton, Address at the International Public Conference on Vac-
cination 2000, (Sept. 9, 2000).
180. COULTER & FISHER, supra note 22, at 181.
181. 18 U.S.C. § 208 was enacted in 1962, but the (b)(3) waiver was added by Congress
in 1989 after the recommendation for the need of more liberalized waivers made by a com-
mission appointed by President Bush during that same year. See Conflicts of Interest and
Vaccine Development supra note 23, (statement of Marilyn L. Glynn, General Counsel, Of-
fice of Government Ethics), at http://www.house.gov/reformlhearingslhealthcare
/00.06.15/glynn.pdf This commission concluded that the government needed to be liberal with
conflict of interest rules in order to obtain advice from individuals with expertise in the pri-
vate sector. Id. It recommended that federal agencies be given broad discretion to grant indi-
vidual waivers if the need for the individual's services outweighed the perceived conflict of
interest. Id. The commission's report is entitled Report of the President's Commission on
[Vol. 37
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opportunity to interpret the application of this section, it has interpreted the
meaning of 18 U.S.C. § 434, the predecessor of 18 U.S.C. § 20 8 ." In United
States v. Mississippi Valley Generating Co.,"' the Supreme Court noted:
The statute is directed at an evil which endangers the very fabric of a de-
mocratic society, for a democracy is effective only if the people have faith
in those who govern, and that faith is bound to be shattered when high of-
ficials and their appointees egage in activities which arouse suspicions of
malfeasance and corruption.
The majority cited a Biblical admonition in which "no man can serve
two masters"' and stated that the statute's purpose is to insure "honesty in
the Government's business dealings" by preventing federal employees from
"advancing their own interests at the expense of the public."'86 The Court
recognized that an "impairment of impartial judgment can occur in even the
most well-meaning men when their personal economic interests are affected
by the business they transact on behalf of the Government."'" The Supreme
Court asserted that the statute is designed to "prevent honest government
agents from succumbing to temptation by making it illegal for them to enter
into relationships which are fraught with temptation." ' In this way, the'
Court explained, the statute is "directed not only at dishonor, but also at
conduct that tempts dishonor."1
89
On July 11, 2000, the chairman of the Committee on Government Re-
form, Congressman Dan Burton, offered an amendment that would halt
funding to the FDA advisory committee if it abused its discretion when
granting waivers on conflict of interest.'" A brief debate ensued on the floor
Federal Ethics Law Reform (March 1989). Id
182. Heisman, supra note 176. "Subsection (a) was modeled on former 18 U.S.C.A. §
434, which disqualified a Federal Government employee who had an interest in the profits or
contracts of a business entity from the transaction of business with such entity. However, sub-
section (a) improved upon the former law by abandoning the limiting concept of the 'transac-
tion of business."' I.
183. 364 U.S. 520 (1961).
184. Id. at 562.
185. Id. at 549 (citing Matt. 6:24).
186. Id. at 548-49 (citing United States v. Chemical Foundation 272 U.S. 1, 18, 47
(1926)).
187. Id. at 550 (citing Rankin v. United States, 98 Ct. Cl. 357 (1943)).
188. Id at 549.
189. Id It does not appear that the liberalized waiver provisions enacted in 1989, (18
U.S.C. § 208(b)(3)), were designed to overrule the purpose of the statute as interpreted by the
Supreme Court. Conflicts of Interest and Vaccine Development (statement of Marilyn L.
Glynn) supra note 176. Rather, the Report of the President's Commission on Federal Ethics
Law Reform suggests that they were designed to provide the Government with the opportu-
nity to better utilize expertise from the private sector. Id.
190. The Agriculture, Rural Development, Food and Drug Administration, and Related
Agencies Appropriations Act, H.R. 68 106 'h Leg., (2000).
None of the funds made available in this Act may be expended for a vaccine-
related Federal advisory committee (Vaccines and Related Biological Products
349
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of the House of Representatives and the amendment was not passed."'
C. Controlling the Abuse of Discretion
Congress has decided that it is not prepared to use its authority over
funding to control conflicts of interest in the vaccine advisory committees.
Nonetheless, other options exist to control the discretion exercised by these
committees in .allowing conflicted members to participate in vaccine poli-
cymaking. These approaches include tightening the current law, implement-
ing a more stringent code, changing the composition of the committees, and
employing an ombudsmen or oversight council at the state level.
1. Tightening the Current Law
On August 10, 2000, Congressman Dan Burton, chairman of the Coin-
Advisory Committee) that grants a waiver on applicable conflicts of interest rules
pursuant to the Federal Advisory Committee Act and sections 202 through 209 of
title 18, United States Code, and regulations issued thereunder.
Id.
191. H.R. 106' Cong. (July 11, 2000), at http:lthomas.loc.gov/cgi-binlquery
/D?r106:1:./temp/-r1O6DtiLUP:e98972 (last visited Oct. 26, 2000). Some excerpts of the de-
bate might prove helpful:
Mr. Burton of Indiana: Mr. Chairman, the health of every American child is af-
fected by decisions made at the Department of Health and Human Services about
vaccines. Those decisions have to be made free of conflicts of interest, and right
now that just is not the case. Health and Human Services relies on two advisory
committees to give scientific advice on vaccine policy. Unfortunately, those advi-
sory committees are dominated by the pharmaceutical industry. HHS routinely
gives doctors with serious conflicts of interest waivers to vote on vaccine policies.
My amendment stands for a simple proposition. We should be getting the best sci-
entific advice possible and it should not be tainted by possible conflicts of interest.
Mr. Skeen: [The] top scientists are few in number and very specialized. Most of
them have worked in research sponsored by industry at some point in their careers.
Mr. Burton: If we grant waivers to those people, we are going to continue the
process which endangers kids in this country.
Mr. Waxman: We have got to have the people who have the knowledge and exper-
tise to be on these advisory committees.. .The conflicts of interest.. .were quite
remote, had nothing to do with vaccine approval. In some cases they involved
people who because of their knowledge and expertise in this area had worked for
pharmaceutical companies because they were the best experts in the country to ad-
vice on those vaccines.
Curiously, this debate has shifted the burden to the Committee on Government Reform to
prove that the advisory committees can operate without conflict of interest, rather than on the
vaccine committees to demonstrate that they cannot operate without these conflicted indi-
viduals. There are over 700,000 doctors in the United States in various specialties. The FDA
and CDC have never explained why none of these 700,000 physicians cannot replace some or
all of the current physicians who have worked for the vaccine manufacturers.
350 [Vol. 37
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mittee for Government Reform, sent a letter to Donna Shalala, Secretary of
Health and Human Services.'9 The letter stated:
It has become clear over the course of this investigation that the VRBPAC
and the ACIP are dominated by individuals with close working relation-
ships with the vaccine producers. This was never the intent of the Federal
Advisory Committee Act... [The] Committee found a flawed process that
placed expediency before vigilance... [V]accines that have not been sub-jected to rigorous scientific review can be dangerous... Please act now to
implement these straightforward recommendations. 193
The congressman offered nine recommendations", designed to tighten
the current law. They included:
stopping the issuing of annual conflict of interest waivers by the CDC;
adopting stricter standards for determining conflicts of interest in areas
such as stock ownership: disallowing recused individuals from participat-
ing in the approval meetings; disallowing members with conflicts of inter-
est from participating in working groups which draft the recommenda-
tions; and holding working group meetings in public. 5
On November 16, 2000, Ms. Melinda K. Plaisier, Associate Commis-
sioner for Legislation for the Department of Health and Human Services re-
sponded.' She stated that conflicted individuals are often used on vaccine
committees because they are the "most active researchers" and the need "for
their expertise outweighs the conflict of interest."'" She also reiterated that
the FDA has the authority to allow conflicted members to participate." In
defending the participation of one conflicted member, Dr. John Modlin, Ms.
Plaisier concluded that his participation was not extensive because "[rln a
transcript of over 6,000 lines, Dr. Modlin speaks [only] 12 times in open ses-
sion for a total of 94 lines."'"
2. Implementing a More Stringent Code
Dr. Erdem Cantekin" has suggested that advisory committee members
should be required to adopt more stringent conflict of interest regulations
192. Letter from Dan Burton, Chairman of the Committee on Government Reform,




196. Letter from Melinda K. Plaisier, Associate Commissioner for Legislation, Depart-
ment of Health and Human Services, to the Honorable Dan Burton, Chairman, Committee on
Government Reform (Nov. 16, 2000) (on file with the author).
197. d at 1 (letter) and at 4 (attachment).
198. Id. at 2 (letter).
199. Id. at 5 (attachment).
200. Erdem Cantekin, Ph.D. is Professor of Otolaryngology at the University of Pitts-
burgh.
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such as the guidelines mandated in the Judicial Code of Conduct."'2 Judges
must abide by the six canons articulated in the code.2" Canon two states, "A
judge should avoid impropriety and the appearance of impropriety in all ac-
tivities.. .A judge must... accept restrictions that might be viewed as bur-
densome by the ordinary citizen.. ."203 Canon three states, "A judge shall
disqualify himself or herself in a proceeding in which the judge's impartial-
ity might reasonably be questioned.. ."' In addition to the code of conduct,
under 28 U.S.C. § 455, federal judges must disqualify themselves when they
know their impartiality might reasonably be questioned °5 or when they have
a financial interest in the subject matter in controversy."l The U.S. Supreme
Court has interpreted 28 U.S.C. § 455(a) to mean that even an appearance of
partiality should be avoided.2"
Although this code applies to all federal judges, its requirements may be
viewed as most significant in respect to district court judges. The decisions
of these judges generally have a direct effect on a limited number of actors-
the plaintiffs (or prosecution) and the defendants. Nonetheless, these judges
must abide by these strict codes of conduct. Conversely, the decisions made
by the members of the vaccine advisory committees effect millions of chil-
dren a year. Considering the numbers of people affected by their decisions,
advisory committee members should abide by codes of conduct at least as
stringent as those of judges.
One way the code is implemented is by requiring judges to submit a re-
cord of financial disclosure when their impartiality may be questioned." 8
Requiring vaccine advisory committee members to also make public any fi-
nancial ties to drug companies would also provide for a heightened level of
public scrutiny and oversight.
201. E-mail from Dr. Erdem Cantekin (Sept. 27,2000) (on file with the author).
202. Judicial Conference of the United States, Judicial Code of Conduct. Quotations are
from the canons themselves and excerpts of the official commentary from the Judicial Con-
ference at http://cSept.iit.edu/codes/coe/judicial-coc.htm (last visited on Oct. 18, 2000).
203. Id.
204. lId
205. 28 U.S.C. § 455(a) cited in Kurtis A. Kemper, J.D., Annotation, Disqualification of
Judge Under 28 USCA § 455(b), Providing for Disqualification Where Judge Has Financial
or Other Interest in the Proceeding, 163 A.L.R. FED. 575 (2000).
206. 28 U.S.C. § 455(b) cited in Kemper, supra at 575.
207. Liljeberg v. Health Services Acquisition Corp., 486 U.S. 847, 860 (1980) ((citing
Hall v. Small Business Administration, 695 F. 2d 175, 179 (5b Cir. 1983)) "The goal of §
455(a) is to avoid even the appearance of partiality. If it would appear to a reasonable person
that a judge has knowledge of facts that would give him an interest in the litigation then an
appearance of partiality is created....").
208. 28 U.S.C.A. § 455(e). "Where the ground for disqualification arises only under sub-
section (a), waiver may be accepted provided it is preceded by a full disclosure on the record
of the basis for disqualification."
[Vol. 37
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3. Changing the Composition of the Committees
Another approach has been suggested by Barbara Loe Fisher. Ms.
Fisher is the only consumer voting member of the FDA's Vaccines and Re-
lated Biological Products Advisory Committee (VRBAPC). 2 She considers
bias to be the major obstacle towards equitable vaccine policymaking and
financial conflict of interest as only one example of bias."' She views the
shared, almost militant, ideology amongst the members of the committee as
the major challenge."'
A pervasive problem that can cause as much bias as financial conflict of
interest is ideology. The federal vaccine advisory committees... are
dominated by infectious disease specialists and public health doctors who
not only have significant financial relationships with vaccine makers but
also embrace a common vision. They see their mission as eradicating
most, if not all, infectious microorganisms from the earth. So when drug
companies produce a new vaccine that is, in effect, a new weapon in their
war on infectious microorganisms, they want everyone to use it. In their
minds, the benefits of using this new weapon to achieve their mission al-
ways outweighs the risks associated with its use. They are conditioned to
believe that casualties are acceptable in order to achieve the mission,
which they define as the 'greater good.' Human nature leads them to want
to dismiss or minimize the risks in order to persuade everyone to cooper-
ate and fight the war.'
Ms. Fisher believes that the advisory committees should include,
"members with expertise in different subspecialties and those with and with-
out varying degrees of financial ties to pharmaceutical firms."' She stresses
the importance of including researchers from the subspecialities of molecu-
lar and cell biology, microbiology, genetics, neuroimmunology, and toxicol-
ogy.214 Currently, these experts do not have a significant opportunity to par-
ticipate in vaccine policymaking."5 It is these subspecialities, Fisher points
out, who have the scientific expertise to address the links between vaccina-
tion and learning disabilities, ADHD, autism, asthma, diabetes, arthritis, epi-
lepsy, multiple sclerosis and cancer."6 Today, the vast majority of scientists
209. In addition to her position on the FDA's VRBPAC to which she was appointed in
1999, Barbara Loe Fisher is president of the National Vaccine Information Center, a non-
profit, educational organization she co-founded with parents of vaccine injured children in
1982. She is the co-author of DPT: A Shot in the Dark (1985), author of The Consumer's
Guide to Childhood Vaccines (1997) and editor of The Vaccine Reaction. Additionally, Ms.
Fisher has served on the National Vaccine Advisory Committee (1988-1991) and Institute of
Medicine Vaccine Safety Forum (1995-1998).
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on the vaccine advisory committees are infectious disease specialists who
have no expertise in these areas.2"7
Ms. Fisher's approach of considering who should be included in vaccine
policymaking as opposed to focusing strictly on who should be excluded, is
an important insight and consideration. Both the integrity and scientific va-
lidity of the vaccine approval process would be greatly improved by replac-
ing some of the current conflicted members with non-conflicted scientists
from these various sub-specialties.
4. Utilizing an Ombudsman or Oversight Council
Although the states are permitted to adopt or reject the federal vaccine
recommendations, they typically adopt every vaccine endorsed by the
CDC."' One reason for this is that states can receive federal finds for each
child who is vaccinated through various federal programs such as the Child-
hood Immunization Initiative."9 Such financial incentives can curtail inde-
pendent decision making among the respective state departments of health.
By acting independently they may risk losing millions of dollars for their
state. In contrast, by adopting the federal vaccine recommendations they can
bring in these needed funds. One solution to this problem is to create a vac-
cine ombudsman program in every state."
A vaccine ombudsman program could have four roles in respect to vac-
cines. First, the ombudsman could undertake or facilitate independent re-
search on childhood vaccination including studying the necessity, efficacy
and safety of federally recommended vaccines. It might be helpful if the
program had the power to subpoena documents such as the raw data in-
volved in vaccine testing. Many of the studies are undertaken by the manu-
facturers and the data is considered proprietar 2. so an independent review
of the data would be valuable. The program's independent research would
permit it to focus on the issues motivating state health departments to adopt
federal vaccine policies.
217. Id. "The expertise and ideology reflected in the membership of these federal vaccine
advisory committees must be diverse and balanced in order to achieve a more enlightened
vaccine licensing and policymaking process." Id.
218. Vaccines: Public Safety and Personal Choice (statement by the Association of
American Physicians and Surgeons on Vaccines submitted by Dr. Jane Orient), supra note 97.("Recommendations' by the Advisory Committee on Immunization Practices are often trans-
formed into mandates by state health departments, with or without specific agreement by the
legislature.....").
219. The CDC's Childhood Immunization Initiative provides performance-based funding
to state and local health agencies that meet or exceed immunization targets.
http://www.theglassceiling.com/health2/heimmuni.htm (last visited Nov. 25, 2000) The FY
1997 budget includes was more than $88 million. Id.
220. The term "ombudsman" comes from the Swedish word that means an investigator
of citizen complaints. See Howard A. Davidson, Applying an International Innovation to Help
U.S. Children: The Child Welfare Ombudsman, 28 FAM. L.Q. 117, 117-18 (1994).
221. See Package Insert, supra note 82.
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Second, the children's vaccine ombudsman office could play a role in-
fluencing legislation and public policies based on its studies and finding.
Third, information regarding the results of the independent studies should be
disseminated. If, for example, the ombudsman finds that the reason behind
the adoption of a particular vaccine is the federal financial incentives then
that information can be disseminated to the public and used to influence pub-
lic policy. Fourth, the vaccine ombudsman program must be careful not to be
seduced into becoming an instrument of the pharmaceutical industry, but in-
stead continually promote children's rights. To accomplish these goals, the
program should be established by legislation so it has the authority to carry
out its purpose.Y
An ombudsman approach would add a layer of objectivity and expertise
between the conflicts of interest present at the federal and possibly the state
levels and the children who will be injected in each state. In addition, it can
decentralize decision making by opening up vaccine policy decisions to
more experts, and allow states to exercise more discretion in determining
whether they need a particular vaccine based on their own distinctive health
demographics.
There are reputable vaccine awareness organizations in most states that
are run by concerned parents. Many of these groups are affiliated with inde-
pendent physicians and scientists. An ombudsman program could align with
these organizations and would, therefore, not need to be created from square
one.
5. The Optimum Strategy to Control Discretion
Each of the four ideas discussed above, have strengths and weaknesses
in respect to meeting the goal of protecting children's health.
Tightening the current law addresses much of the conflict of interest in
vaccine approval, but may be less effective in policing potential abuses in-
volved in vaccine testing. Allowing parents to exercise informed consent is
not addressed.
Implementing a more stringent code of ethics also concerns conflicts in
vaccine policymaking, but does little to address potential conflicts in vaccine
222. The concept of a children's ombudsman is not new. See Malfrid Grude Flekkoy,
he Children's Ombudsman as an Implementor of Children's Rights, 6 TRANSNAT'L L. &
CONTaP. PROBS. 353, 354 (1996). Children's ombudsman programs have been used
throughout various countries of the world including the United States to improve government
accountability in various areas affecting children's lives. See Davidson, supra note 220, at
118
(It coincides with the broader role of the ombudsman for children in other nations,
and encompasses not only improvement of government accountability in the area
of child protective service agencies, foster care, and adoption programs, but also in
the activities of juvenile justice, youth services, and youth corrections agencies, in-
cluding all agencies responsible for the institutional care of children, both during
the day and in residential settings).
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testing unless the code is extended to all scientists involved in vaccine test-
ing, which is not practicable. Besides giving parents the theoretical opportu-
nity to act as a watchdog by scrutinizing the financial records of committee
members, this approach does little to address the need for parental involve-
ment in decision making.
Changing the composition of the advisory committees by providing for
more balanced membership may not eliminate conflicts of interest but will
compensate for it with a rich diversity of scientific viewpoints. In addition, if
membership in the committee is opened to more parents, this approach will
provide for greater parental involvement in vaccine policymaking.
The idea of using an ombudsman does not have a direct impact on either
vaccine testing or approval. By acting in a mediation fashion, however, a
team of medical experts and parents with diverse viewpoints can provide a
valuable service to their state's children. An objective body whose purpose it
is to look out for children, challenge assumptions and share information with
parents would help neutralize any fraud that was part of the original federal
recommendation.
None of these four approaches should be thought of as mutually exclu-
sive. Valuable synergies may develop from implementing more than a single
approach.
The CDC and FDA are likely to reject every one of these ideas. They
will argue that the best experts are already making vaccine decisions and that
the conflicts of interest that exist do not interfere with the quality of their
policymaking. When faced with this explanation during the congressional
hearing, Congressman Burton replied, "Can the FDA and CDC really be-
lieve that scientists are more immune to self-interest than other people?"223
Another reason for inaction will likely be that the advisory committees are
not the last word, but actual recommendation and approval is made by FDA
and CDC officials 2 While this is may true in theory, in fact every recom-
mendation made by the federal advisory panels in the last 10 years has been
endorsed by federal public health officials.'
D. Protecting Children in an Inadequate System
In addition to what has already been discussed, the legal system pro-
223. Conflicts of Interest and Vaccine Development, supra note 23 (opening statement
by Congressman Dan Burton), at http:llwww.house.gov/reform/hearings/healthcare/00.06.15
/opening-statement.htm.
224. Id. (statement by Dixie E. Snider).
225. See id. at 90 (conversation between Congressman Burton and Linda Suydon):
Congressman Burton: "So for the past 10 years, the recommendations of the advi-
sory panels have pretty much been followed 100 percent?"
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vides a number of other potential remedies to protect children from unsafe or
unnecessary vaccines. One strategy is tort liability, but federal officials who
grant waivers to conflicted doctors and scientists are free from this liability
because they are acting within their discretion 6 Nonetheless, there are at
least two creative approaches that can send a not so subtle message to the
federal government and the manufacturers that people are watching for fraud
and poor fiscal decision making in respect to unnecessary or unsafe vac-
cines. These approaches are taxpayer derivative suits and Qui Tam claims
under the false claim act and they are available to concerned physicians or
parents who wish to use the law to exercise oversight over the vaccine poli-
cymakers, albeit, indirectly.
1. Taxpayer Derivative Suit
Public officials are empowered to make decisions regarding how gov-
ernment's limited resources may be distributed for the purchase of goods
and services. Because taxes are the major source of these resources, taxpay-
ers have an interest in how well this function is performed. If, for example,
too much money is spent on a good of low priority, this will leave insuffi-
cient funds for more pressing priorities. Taxpayer suits are one legal mecha-
nism to hold public officials accountable. 7 Generally, taxpayers' suits are
defined as:
Proceedings brought by one or more taxpayers on behalf of themselves as
representatives of a class similarly situated within a taxing district or area,
upon a ground which is common to all members of the class, and for the
purpose of seeking relief from illegal or unauthorized acts of public bodies
or public officials which acts are injurious to their common interests as
such taxpayers.228
Both the states and the federal government permit taxpayer suits. But
the federal government requires the suit to relate to a constitutional viola-
tion. 2 9 In contrast, some states allow a suit when the taxpayer can make a
226. See, e.g., Berkovitz by Berkovitz v. U.S. 484 U.S. 1003 (1988).
227. Susan L. Parsons, Taxpayers' Suits: Standing Barriers and Pecuniary Restraints, 59
"tBw. L.Q. 951 (1986).
228. Id. at 951-52 (quoting 74 AM. JUR. 2D Taxpayers' Actions § 1 (1974)).
229. In Flast v. Cohen, the Supreme Court created a two-prong test for federal taxpayer
suits. Flast v Cohen, 392 U.S. 83 (1968). The first prong requires that the expenditure is pur-
suant to a Congressional taxing and spending decision. Id. at 102. An incidental expenditure
related to a regulatory statute will not meet this prong. Id. The second prong, requires that the
cause of action relates to a constitutional violation. Id. See, e.g., Parsons, supra note 227. The
few suits that have had standing have alleged that the federal government acted illegally
within the meaning of the I' Amendment when it purchased goods for religious organizations
such as church-related schools or universities or denominational stamps. See, e.g., Lemon v.
Kurtzman, 403 U.S. 602, (1971), Flast v. Cohen, 392 U.S. 83 (1968), Tilton v. Finch 312 F.
Supp. 1191 (D.C. Conn. 1970) (books for church-related schools); Protestants and Other
Americans, etc. v. Watson, 407 F.2d 1264 (D.C. Cir. 1968) (Christmas stamps).
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prima facie case that the government used funds to purchase unnecessary
goods or services."
Both federal and state funds are expended for the purchase of vaccines"3
and the dollars expended are significant. For example, Prevnar may cost the
federal government approximately $448.5 million a yearY2 If the product
works, it is expected to save the lives of approximately 42 children. 3 In ad-
dition to Prevnar, there are eight other vaccines paid for by federal or state
funds.'
230. See Parsons, supra note 227, at 955. Each state has different requirements. Id.
Some states (i.e. Texas) requires that a bureaucrat violates the law or the state constitution,
but in general there are four hurdles: 1) Some jurisdictions require that taxes must have in-
creased to pay for the disputed good or service; 2) Eight states require a bond to be posted to
cover the defendant' litigation costs; 3) Some jurisdictions will not pay attorneys fees even if
the taxpayer is the prevailing party; 4) Most jurisdictions require that the taxpayer demon-
strate that the state's purchase is illegal or at least unnecessary and not merely within the dis-
cretion of an acting official. Id. There is also a pecuniary interest required but this is usually
satisfied whenever there's a waste or unlawful expenditure of public monies. Id. at 953. The
remedies of a taxpayer action are at equity and a prevailing plaintiff can seek to enjoin the
expenditure or obtain a writ of mandamus to compel an official to perform a specific duty.
See, e.g., City of Stuttgart v. McCuing, 234 S.W.2d 209, 211-13 (Ark. 1950); Bernstein v.
Krom, 111 N.J. Super. 559, 561-63 (1976), cited in Parsons, supra note 227, n. 102.
In New York and Pennsylvania, taxpayers have standing to bring suits based on misapplica-
tion of state funds. This suggests, a cause of action can be brought for vaccines purchased
with state dollars. "[Taxpayer has course of action to enjoin wrongful expenditure, misap-
propriation, misapplication, or any other illegal or unconstitutional disbursement of state
funds or state property." N.Y. State Fin. Law § 123(b) (McKinney 1974 & Supp. 1986) cited
in 'Parsons, supra note 227, n.88. See also New York State Builders Ass'n v. State, 98 Misc.
2d 1045 (N.Y. 1979) cited in Parsons, supra note 170, at 951, n.112. ("[in this case] a tax-
payer suit had standing for "misapplication of state funds"). See also Price v. Philadelphia
Parking Auth., 422 Pa. 317, 326 (Pa. 1966) cited in 74 AM. JUR. 2D Taxpayer's Actions § 16,
n.26 (1974).
231. There are a variety of sources of government funds for the purchase of vaccines,
including: the Vaccines for Children Program (VFC), § 317 of the Public Health Service Act,
and various state revenues. INSTITUTE OF MEDICINE, CALLING THE SHOTS: IMMUNIZATION
FINANCE POLICIES AND PRACTICES § 3, 49-50 (2000) at
http://www.books.nap.edu/0309071291/html/69/html. Federal entitlements subsidize VFC
and "Section 317" vaccine purchases. Id. Approximately 12% of all state-supplied vaccines
are purchased with state funds, VFC accounts for 65%, and "Section 317" accounts for 22%.
Id.
232. The CDC price for Prevnar for one child is approximately $184 ($45.99 per dose *
4 doses). CDC Vaccine Price List, -at http:llwww.cdc.gov/nip/vfc/cdc-vaccine-price-list.htm
(last visited on Oct. 27, 2000). There are approximately 7.5 million children under two years
of age. THE NEw YORK TiMEs ALMANAC, supra note 92, at 277. Sixty-five to seventy percent
of those children will have their vaccines purchased by the VFC. See Henry Grabowski and
John Vernon, The Search for New Vaccines: The Effects of the Vaccines for Children Pro-
gram, presented by the American Enterprise Institute for Public Policy Research,
http://www.aei.org/bs/bs8117.htm (last visited on Oct. 27, 2000).
($184) (7.5 million) ) (.65) = $897,000,000. The doses are spread over two years so the an-
nual cost is $862,875,000/2 = $448,500,000.
233. See supra note 149 and accompanying text.
234. These vaccines are 1) Varicella, 2) Polio, 3) MMR, 4) Influenza, 5) DPT, 6) Hib, 7)
Hep A, 8) Hep B. See VFC ACIP Resolutions, at http://www.cdc.gov/nip/vfc/acip.htm (last
visited Oct. 27, 2000).
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Theoretically, it can be argued that the procurement of unnecessary,
poorly tested, or dangerous vaccines is a misapplication of state and federal
funds. Such an argument, if successful, would keep these products away
from children, and also allow these monies to be expended on more essential
public health and welfare needs.235
2. Qui Tam Litigation Under the False Claims Act
The Qui Tam provision of the False Claims Act (FCA) allows whistle-
blowers to sue parties who fraudulently bill the government.236 This law has
been used successfully in cases where defense contractors and subcontrac-
235. For example, can the millions of dollars spent on Prevnar be better expended to pro-
tect not only those few who will be stricken by invasive pneumococcal disease, but others as
well? Can this disease be prevented through a wiser expenditure of funds? One risk factor for
this disease is being HIV positive. 1997 REDBOOK: REPORT OF THE COMMITTEE ON INFECTIOUS
DISEASES 411 (1997). Can some portion of the money be utilized to address this factor? What
about using the funds to address those issues that have the biggest impact on children? Can
the money be used to improve living conditions, nutrition or housing? Accidents around the
home kill approximately 7,000 children every year and seriously injure 50,000 more. See
Home Safety, at http:llwww.opfer.comlhomeasafenotsorry/ (last visited Oct. 28, 2000). In
addition, reports of child abuse totaled 2.9 million cases between 1985 and 1992. See David-
son, supra note 220, at 120 (quoting WILLIAM J. BENNETT, THE INDEX OF LEADING CULTURAL
INDICATORS 11 (Heritage Foundation Mar. 1993) (citing statistics from American Humane
Association and the National Committee for Prevention of Child Abuse)). Millions of dollars
will be expended from federal and state treasuries for, Prevnar, a vaccine that may save the
lives of about 42 children. See supra notes 148-50 and accompanying text. Can some of this
money be better spent in these areas? These are some of the questions taxpayer plaintiffs may
ask if they allege a cause of action for misuse of funds.
236. Congress enacted the Federal False Claims Act (FCA) in 1863 to protect the Union
from unscrupulous suppliers of war materials. See 31 U.S.C. §§ 3729-3731 (West,
WESTLAW. through P.L. 106-274, approved Sept. 22, 2000). In 1863, the United States was
in the middle of the Civil War. To provide the weapons and materials for war, the Union con-
tracted with various manufacturers. Some of these manufacturers proved themselves to be
corrupt. According to an article written in 1864, "For sugar [the government] often got sand;
for coffee, rye; for leather, something no better than brown paper; for sound horses and mules,
spavined beasts and dying donkeys; and for serviceable muskets and pistols, the experimental
failures of sanguine inventors, or the refuse of shops and foreign armories." Tomes, Fortunes
of War, 29 HARPER'S MONTHLY MAG. 228 (1864). F. SHANNON, THE ORGANIZATION AND
ADMINISTRATION OF THE UNION ARMY, 1861-1865, at 54-56 (1965) (Quoted in U.S. ex rel.
Newsham v. Lockheed Missiles and Space Co., Inc. 722 F. Supp. 607, 609 (N.D. Cal. 1989)).
The Act was subsequently amended in 1943 and 1986 and provides that anyone who presents
a false financial claim to the federal government shall be liable for double or treble damages
and civil penalties of up to $10,000 per false claim. See 31 U.S.C.A. § 3729. Under the qui
tam provisions of the Act, any person with the appropriate knowledge may bring a civil action
to recover damages and penalties. See 31 U.S.C.A. § 3730(b)(1). Qui tam is short for the
Latin phrase "qui tam pro domino rege quam pro se ipso in hac parte sequitur," which means
"who pursues this action on our Lord the King's behalf as well as his own." Vermont Agency
of Natural Resources v. U.S. ex rel. Stevens 529 U.S. 765, 769 (2000). To bring a qui tam ac-
tion a parent will need access to some "inside information" on fraudulent practices.
AMERICAN BAR ASSOCIATION, QuI TAM LITIGATION UNDER THE FALSE CLAIMS ACT 37 (How-
ard W. Cox & Peter B. Hutt II eds., 2d ed. 1999) [hereinafter Qul TAM LITIGATION] ("Public
disclosures are barred unless asserted by an original source of the information").
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tors perpetrate fraud on the government."M
The plain language of the act, its legislative history, and a recent Su-
preme Court decision suggest that the FCA could also be used to penalize
vaccine and drug manufacturers who falsify their studies or sell an unsafe or
defective pioduct to the government."8
The statute states that any person is liable who "knowingly makes, uses,
or causes to be made or used, a false record or statement to get a false or
fraudulent claim paid or approved by the Government."" Actual intent does
not have to be proved.' Congress recognized that it is very difficult to de-
tect fraud without the assistance of private citizens "who are either close ob-
servers or otherwise involved in the fraudulent activity.""24 And recently, the
Supreme Court concluded that, "the Act was intended to reach all types of
fraud, without qualification, that might result in financial loss to the Gov-
ernment. '242
When the government subsidizes the testing of vaccines and the evalua-
tion is carried out in a knowingly fraudulent way, a Qui Tam action would
be theoretically possible against the manufacturer. This is no different than a
defense contractor who makes knowing misrepresentations regarding the
testing and development of a missile system. In addition, the action could
theoretically be brought when the federal government does not finance the
testing, but rather purchases the vaccines. As discussed supra, the state and
federal governments are the largest purchasers of vaccines.243 If the federal
government spends millions of dollars on a vaccine that is unsafe or ineffec-
tive it is not getting what it paid for.2" This is no different than the unscrupu-
237. See, e.g., U.S. ex rel. Madden v. General Dynamics Corp. 4 F.3d 827, 829 (9' Cir.
1993) (relator alleged that the defendant, a large defense contractor, "made misrepresentations
to the United States Navy concerning the testing and development of the Phalanx close- in
missile system"). See U.S. ex rel. Kelly v. Boeing Co. 9 F.3d 743 (9" Cir. 1993) (relator
claimed that Boeing improperly charged to the government certain facilities lease costs).
238. "The starting point for interpreting a statute is the language of the statute itself. Ab-
sent a clearly expressed legislative intention to the contrary, that language must ordinarily be
regarded as conclusive." U.S. ex rel. Precision Co. v. Koch Industries, Inc. 971 F.2d 548, 552
(10th Cir. 1992) (quoting Consumer Products Safety Comm v. GTE Sylvania, Inc., 447 U.S.
102 (1980)).
239. Knowingly can mean either: (1) having actual knowledge of the information; (2)
acting in deliberate ignorance of the truth or falsity of the information; or (3) acting in reck-
less disregard of the truth or falsity of the information. See 31 U.S.C.A. § 3729(b).
240. See id.
241. "The legislative history indicates that Congress sought to encourage more private
enforcement of the FCA because [dletecting fraud is usually very difficult without the coop-
eration of individuals who are either close observers or otherwise involved in the fraudulent
activity. Yet in the area of Government fraud, there appears to be a great unwillingness to ex-
pose illegalities." S. Rep. No. 345 at 4, reprinted in 1986 U.S.C.C.A.N. at 5269, quoted in
U.S. ex rel. Kelly v. Boeing Co., 9 F.3d 743, 745 (9th Cir 1993).
242. "The Senatorial sponsor of this bill broadly asserted that its object was to provide
protection against those who would 'cheat the United States'." 317 U.S. 537, 544 (1943)
(quoting Congressional Globe, 37th Cong., 3rd Sess, 952).
243. INSTITUTEOFMEDICINE, supra note 231.
244. Because the False Claims Act is a federal statute it would only apply to fraud that
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lous defense contractors of 1863 selling the government donkeys when
horses were ordered. 5
Any parent or group of parents would theoretically have a right to bring
such an action if they are aware of "inside" information pertaining to the
vaccine's fraudulent testing or manufacturing.2' After the suit is filed, the
government would have an opportunity to intervene and take over the law-
suit. Alternatively, if the federal government opts out of such a suit, the indi-
vidual or individuals would still have the opportunity to bring the suit for-
ward. Moreover, the Act provides a generous incentive for private citizens to
pursue such actions. Citizens are entitled to up to 30% of the damages and
damages can run into the millions of dollars.2 7 Such an approach, if success-
ful, would serve to protect children from fraudulent or dangerous vaccines
and also punish manufacturers for acting capriciously.
3. The Optimum Alternative Strategy
Taxpayer derivative suits and Qui Tam actions are available to con-
cerned physicians, parents and drug company employees who wish to use
the law to exercise limited and indirect oversight over the vaccine policy-
makers. In some states a successful taxpayer derivative suit will require suf-
ficient evidence to prove that the decision to purchase a vaccine violated a
state law or constitution. Other states have a lower burden requiring the
plaintiff to prove that the purchase was an irresponsible one and a waste of
taxpayer money. The success of any Qui Tam action will be dependent on
the degree to which the "inside" information is capable of proving fraud.
Theoretically, any such information related to the vaccine testing (if the gov-
ernment subsidized it) or related to the vaccine's safety, efficacy and neces-
sity (if the government purchased it) would be fair game.
impacts the federal treasury.
245. U.S. government purchase of dangerous or unnecessary vaccines is arguably indis-
tinguishable from recent cases in health care fraud where health care services were medically
unnecessary or because the quality of the healthcare was substandard. See Qui TAM
LITIGATION, supra note 236, at 93-94 (citing United States ex rel Dorsey v. Dr. Warren E.
Smith Comm. Mental Health/Mental Retardation and Substance Abuse Ctrs., 1997 U.S. Dist.
LEXIS 9424 (E.D. Pa. 1997)).
246. "Riley has not offered any binding or persuasive authority that the Supreme Court
has either implicitly or explicitly closed the door on arguments that qui tam relators under the
FCA lack standing." Riley v. St. Luke's Episcopal Hosp.,196 F.3d 514, 535 (5th Cir. 1999).
247. If the government intervenes, a qui tam plaintiff is now guaranteed 15% and may
recover up to 25% of any amount recovered by the government. Qui TAM LITIGATION supra
note 236, at 93-94. If the government does not intervene, a qui tam plaintiff is guaranteed
25% and may recover up to 30% of any amount recovered for the government. Id. A qui tam
plaintiff also now has a right to recover reasonable attorney's fees. Id.
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IV. REDEFINING THE PROBLEM
A. Defining A Preventive Law Approach
The Preventive Law model is founded on the principle that preventing a
problem from occurring is generally easier, cheaper and better than reacting
after the problem has already happened. 48 In respect to the conflicts of inter-
est in vaccine policymaking there are two assumptions: 1) we need vaccines;
2) we need vaccines that are produced and approved without conflicts of in-
terest. A preventive law approach challenges both of these assumptions.
B. Do Children Need More Vaccines?
Do children need twenty injections and thirty individual vaccines in
their first eighteen months of life? Should healthy children be targeted for
the seventy-five new vaccines in the pipeline?249 Pediatricians, scientists and
parents are asking these questions. In fact, a small but growing number of
doctors believe that "with some immunizations, the danger of taking the shot
may outweigh that of not taking it."''
A sincere and open-minded examination of the need for vaccines by
non-conflicted scientists, physicians and public health experts would be the
first step. Another step would be to apply the "gold standard" of scientific
testing. No large-scale study has ever been undertaken to compare the rates
of any disease among vaccinated and unvaccinated children to determine the
ultimate impact of vaccination.
C. Do Children Need Vaccines Devoid of Conflicts of Interest?
If, after objective scientific studies, the question of do children need all
of these vaccines is answered affirmatively, then preventive law can still of-
fer a strategy to address the conflict of interest. Vaccine policymaking is
248. Thomas D. Barton, Presentation to Health Law: Selected Problems (Sept. 19, 2000).
249. "Big Pharma now views vaccines as a great opportunity for growth... [there are
more] than 75 different vaccines now in various stages of clinical trials." See Bruce Goldman,
Why Vaccines Are Hot, Signals, Jan. 18, 1999 at http://www.signalsmag.com/signalsmag.nsf.
250. See ROBERT S. MENDELSOHN, MD, CONFESSIONS OF A MEDICAL HERETIC 144
(1979). For example, Dr. Robert Mendelsohn, a pediatrician and past chairman of the Medical
Licensure Committee for Illinois, calls the value of diphtheria vaccine "questionable" and
cites studies in which the rare outbreaks of diphtheria occurred among people who were vac-
cinated. Id. He has also challenged the need for the pertussis vaccine stating, "Only about half
of its recipients benefit, and the possibility of high fevers, convulsions, and brain damage is
too high to ignore." Id. In respect to the measles vaccine he has said, "Any doctor who has
decades of experience with measles knows that... among well nourished.., children the
incidence [may be] one in 100,000. Meanwhile the vaccine is associated with encephalopa-
thy.. .[and] retardation, hyperactivity, asceptic meningitis, seizures, and hemiparesis (paraly-
sis of one side of the body)." Id. In respect to the rubella vaccine he has said, "[it] may do
more harm than good." Id.
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centralized"1 and therefore any conflicts of interest effect millions of chil-
dren. Must vaccine decision-making rest with a handful of men and women
who are unfamiliar with the health history of a particular child?' The two
groups who know the health status of a child best are the child's parents and
pediatricians.m Yet, the decision whether a child needs three hepatitis B
vaccines or a chicken pox vaccine or four doses of Hib are made hundreds or
thousands of miles away by complete strangers.'m
We assume that parents love their children and, when properly in-
formed, will make decisions in their child's best interest. If parents and phy-
sicians are provided with full disclosure regarding the risks and benefits of
vaccination then they can make intelligent decisions for their children. In
addition, if the decision making power is shifted from the government to
parents, then parents can exercise informed consent." Currently, parents are
handed a brief checklist that offers a very incomplete description regarding
each vaccine."6 If the parent objects, and the child is not vaccinated, at worst
251. See generally Majority Staff Report, supra note 29.
252. There is growing scientific evidence that children's immune systems and immune
responses are not identical. See, e.g., T. Shirakawa, et al., The Inverse Association Between
Tuberculin Responses and Atopic Disorder, 275 SCIENCE 77-79 (1997) ("Human immune re-
sponses are heterogeneous .... ); IMMUNE DEFICIENCY FOUNDATION, THE CLINICAL
PRESENTATION OF THE PRIMARY IMMUNODEFICIENCY DISEASES: A PRIMER FOR PHYSICIANS
(1992).
253. "We cannot continue a policy of 'treat every child the same' for vaccines because
every immune system is different." E-mail from Mary N. Megson, M.D., F.A.A.P (Oct. 9,
2000) (on file with the author).
254. See generally Vaccines: Public Safety and Personal Choice (statement by the Asso-
ciation of American Physicians and Surgeons on Vaccines submitted by Dr. Jane Orient) su-
pra note 97.
(Public policy regarding vaccines is fundamentally flawed. It is permeated by con-
flicts of interest. It is based on poor scientific methodology (including studies that
are too small, too short, and too limited in populations represented), which is,
moreover, insulated from independent criticism. The evidence is far too poor to
warrant overriding the independent judgments of patients, parents, and attending
physicians, even if this were ethically or legally acceptable. Indeed, evidence is
accumulating that serious adverse reactions are being ignored.)
255. "The remote but real risk of serious disease that attends vaccinations must be scru-
pulously and comprehensively disclosed to the parents of the children that await vaccination."
Vaccines: Public Safety and Personal Choice (statement of Marcel Kinsbourne, M.D.), supra
note 60. See also Karin Schumacher, Informed Consent: Should it be Extended to Vaccina-
tions, 22 TJLR 89 (1999).
256. The CDC publishes a vaccine information sheet for each major childhood vaccine
and this sheet must be provided to the parent or legal guardian of the child. See 42 U.S.C.A. §
300aa-26(a) (West, WESTLAW through P.L. 106-274, approved Sept. 22, 2000). These
sheets typically exclude the overwhelming majority of the information provided in the manu-
facturer's inserts. For example, the sheet for Pneumococcal Conjugate Vaccine (i.e. Prevnar)
states that "In clinical trials, pneumococcal conjugate vaccine was associated with only mild
reactions." Centers for Disease Control, Vaccine Information Statement (Interim) Pneumo-
coccal Conjgate Vaccine, July 18, 2000 (on file with author). This statement neglects to men-
tion the more serious reactions associated with the vaccine and reported in the insert. See
Package Insert, supra note 82. For information on the CDC's Instructions for Use of Vaccine
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the parent will be prosecuted, and at best the child may not be allowed to at-
tend school.' However, a very different approach would result if parents
had autonomy and full disclosure in respect to vaccine decision making for
their children. Below is a hypothetical example of how an excerpt from a
"full disclosure" vaccine information sheet might appear for Prevnar.
> Prevnar is marketed to prevent pneumococcal infections that can cause
earaches, meningitis, bacteremia and pneumonia.261
> Invasive pneumococcal disease can be a life-threatening disease to some
children.
> Each year, approximately 42 children (under the age of two) die from
pneumococcal meningitis.2"
> Children who are at risk for this disease are those who have pre-existing
conditions such as: Hodgkin's disease, congenital or acquired immuno-
deficiency (including HIV), nephrotic syndrome, some viral upper respi-
ratory tract infections, splenic dysfunction, splenectomy and organ
transplantation.2 3
> The vaccine was tested for safety and efficacy by the manufacturer.2"
> No long-term tests were done looking at potential associations between
the vaccine and chronic autoimmune diseases.26
> The vaccine was not tested to determine if it was carcinogenic.26
> The vaccine does interfere slightly with the efficacy of two other vac-
Information Materials see http://www.cdc.gov/nip/publications/ VIS/vis-Instructions.pdf (last
visited Mar. 7, 2001). For information on the requirement to provide these materials see 42
U.S.C. § 300aa-26. For information on the Pneumococcal Vaccine Conjugate Sheet see CDC
website (last visited on 3/7/2001), at http:/www.cdc.gov/nip/publicationslVIS/vis-
pneumoConjugatelnterim.pdf.
According to Jane Orient, M.D.:
Information given to parents about [the hepatitis B vaccine] often does not meet
the requirement for full disclosure. For example, it may state that 'getting the dis-
ease is far more likely to cause serious illness than getting the vaccine.' This may
be literally true, but it is seriously misleading if the risk of getting the disease is
nearly zero (as is true for most American newborns). It may also be legalistically
true that 'no serious reactions have been known to occur due to the hepatitis B re-
combinant vaccine.' However, relevant studies have not been done to investigate
whether the temporal association of vaccine with serious side effects is purely co-
incidental or not.
Vaccines: Public Safety and Personal Choice (statement by the Association of American Phy-
sicians and Surgeons on Vaccines submitted by Dr. Jane Orient), supra note 97.
257. Kitch, supra note 26, at 1175 and Orenstein et al., Public Health Considerations-
United States, in VACCINES, supra note 26, at 1022.
258. Package Insert, supra note 82.
259. Supra note 149.
260. COMMrITEE ON INFECTIOUS DISEASES AMERICAN ACADEMY OF PEDIATRICS 1997
RED BOOK: REPORT OF THE COMMITEE ON INFECTIOUS DISEASES 411 (1997).
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cines.267
> One doctor believes it could lead to diabetes.2"
> The federal recommendation and approval of the vaccine were under-
taken by committees of whom some of the members had financial ties to
the manufacturer.2 9
> The American Academy of Pediatricians calls Prevnar the most reacto-
genic of all childhood vaccines.2 0
On its face this kind of full disclosure may appear preposterous but pro-
viding the truth is critical where children's health is at stake even if it re-
fleets poorly on the manufacturer and on current vaccine policymaking. By
making all the issues visible and allowing for parental autonomy, parents
would be able to factor this information into their decision making. Granted,
it would still be a benefit to have vaccines devoid of conflict of interest, but
it would no longer be a necessity upon which parents are totally dependent.
In this sense, full disclosure compensates for conflict of interest.
D. The Feasibility of a Preventive Law Approach
Taking a preventive law approach addresses conflicts of interest in vac-
cine testing and policymaking and the importance of parental informed con-
sent. If a vaccine is not needed, all the issues in respect to this single vaccine
become moot. If parents are given full disclosure, than any fraud loses its
power to do harm by becoming fully exposed. Approaches like these chal-
lenge the status quo and ask people to confront their preconceptions. It is for
that reason, that these ideas would most likely enjoy a very hostile reception.
The CDC and FDA would likely argue that parents should not have the right
to full autonomy in respect to vaccines because the public health is different
than an individual's health. While they are different, this argument presup-
poses that vaccinating one child protects another. Many of the new vaccines
have not been tested to prove whether such an assumption is true.
V. CONCLUSION
Children once had to be protected from disease. Today, they must be
protected from a system that "shoots first and asks questions later."''6 Integ-
rity must be injected back into the sphere of vaccine policymaking. Children
have a right to get shots that are both necessary and safe, and not tainted
with conflicts of interest. Pneumococcal meningitis disease takes the lives of
264. Id.
265. Classen supra note 164.
266. See supra notes 154-168 and discussion.
267. Overturf & Committee on Infectious Diseases, supra note 168.
268. Michael Belkin Address at the International Public Conference on Vaccination
2000, (Sept. 10, 2000), at http:llmercola.com/2000/oct/22/shoot_first.htrn. Mr. Belkin's
healthy daughter died after being administered a hepatitis B vaccine. Id.
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approximately 42 Children a year." Rotavirus claims the lives of twenty
children."' Hepatitis B kills fewer than 15 children."' There is data to sug-
gest that at least one vaccine may be causing more death and injury than the
illnesses that the vaccine was designed to prevent. Yet, billions of dollars are
paid to pharmaceutical manufacturers on poorly tested and potentially dan-
gerous vaccines to prevent diseases that are hardly epidemics."' During the
congressional hearing on Vaccine Conflict of Interest, Congressman Gilman
summed up these concerns:
[The] apparent ties between the pharmaceutical industry and the Federal
Drug Administration and Centers for Disease Control advisory committee
members results in more than an ethical question.... The breach of integ-
rity in vaccine development has culminated in the serious need for re-
form.... Human life should not be undermined or compromised for per-
sonal or financial ties that advisory members may have to the
pharmaceutical industry. 3
With at least seventy-five more vaccines in the pipeline, vaccines are
big business.274 Manufacturers and their representatives in government will
not surrender their authority without being confronted. For this reason, a va-
riety of solutions should be pursued. The loopholes that permit these con-
flicts should be closed. Higher standards of accountability should be en-
forced. The advisory committees should be opened to representatives from
all the medical and scientific subspecialties that can offer a valuable perspec-
269. See supra note 149.
270. See supra note 90.
271. See supra notes 92-100.
272. Miguel A. Faria, Jr., MD, Vaccines (Part II): Hygiene, Sanitation, Immunization,
and Pestilential Diseases, at http://www.haciendapub.com/article36.htm (last visited Nov. 1,
2000).
Before 1960, there were only a few vaccines that were administered for rampant
diseases that were known to have posed a clear and present danger, an immediate
and imminent epidemiologic threat. Today, it seems that the public health estab-
lishment is obsessed with developing vaccines against every conceivable microor-
ganism, and these government programs are bent to include everyone, every child,
every infant in the immunization loop.
Id. See also telephone interview with F. Edward Yazbak, M.D., F.A.A.P. (Oct. 9, 2000) (on
file with author). Vaccines are not necessary for every single disease without a thorough risk-
benefit analysis by independent doctors and scientists. Id. Dr. Yazbak practiced pediatrics for
35 years. Id. He was the Assistant Clinical Director, Charles V. Chaplin Hospital in Provi-
dence, past President of the Medical Staff and Director of Pediatrics at Woonsocket Hospital,
Deputy Director for Pediatrics, Child Development Study, Brown University with the Na-
tional Institutes of Neurological Diseases and Blindness. Id.
273. Conflicts of Interest and Vaccine Development, supra note 23, at 106-07 (oral tes-
timony of Congressman Gilman (see transcript at lines 2521-2563)).
274. See Goldman, supra note 249. "Wyeth has been touting the growth potential of its
vaccine line. At an analysts meeting in September, the company predicted an annual global
growth rate for the business of 34% from 1997 to 2001.: Smithkline, AHP Vaccine Businesses
are Logical Merger Candidate, 60 (No. 4) PINK SHEET 8 (1998).
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tive in respect to vaccine safety. Vaccine ombudsmen programs whose only
focus is the health of children should be implemented in every state to act as
mediator between the federal decision-makers and the state's population of
children. Taxpayer derivative actions and Qui Tam litigation should be filed
where appropriate to put the federal government and manufacturers on no-
tice that they are being watched for malfeasance. Full disclosure should be
practiced and autonomy should be provided so that parents have the infor-
mation they need to make informed decisions before the shots are adminis-
tered. In the final analysis, no less than the health of our nation's children is
dependent on our efforts.
"....Man, proud man!
Dress'd in a little brief authority,-
Most ignorant of what he's most assured,
His glassy essence,-like an angry ape,
Plays such fantastic tricks before high heaven
As makes the angels weep.
-WILLIAM SHAKESPEARE, MEASURE FOR MEASURE act 2, sc. 2.
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